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Abstract
Death-associated protein kinase1 (DAPK1) is a calcium/calmodulin (Ca2+/CaM)
regulated serine/threonine kinase. An increasing body of evidence supports the
significance of DAPK1 protein in cancer and CNS diseases. The role of DAPK in
peripheral nerve regeneration and neuropathic pain remains completely unexplored. The
aim of this study is to investigate the expression pattern of DAPK1 along with key proand anti-apoptotic cell signaling molecules (p53, Bax, Akt, ERK5, p38) and to verify the
possibilities of DAPK1-NMDA NR2B relationship in dorsal root ganglion neurons
(DRG) after 2 hours, 7 days and 14 days following a sciatic nerve injury. Gene
expression analysis and immunohistochemistry were used to assess the effects of nerve
injury. ATF3 was used as a neuronal injury marker. The results showed that DAPK1
mRNA was expressed and translated to functional protein in normal DRG neurons. Soon
after a sciatic nerve injury (2 hours), DAPK1 was significantly up-regulated (p<0.05, 2.2
fold) in the injured L4 and L5 DRG compared with the contralateral uninjured side.
However, 7 days after axotomy a profound decrease was observed in the DAPK1 level,
with a further reduction that reached its minimum level at 14 days postoperatively. In
addition, 7 days after injury, most of the DAPK1 positive injured neurons (76.11%)
were ATF3 positive, while after 14 days DAPK1 immunoreactivity significantly
decreased (53.89%) in injured ATF3 positive neurons. Interestingly, DAPK1, p53 and
Bax exhibited a similar expression pattern in axotomized lumbar DRG. The results also
revealed that a sciatic nerve injury had no effects on the gene expression of ERK5, p38
and Akt at every time point. Moreover, NMDA NR2B mRNA expression increased after
7 days and continued to up-regulate significantly until 14 days postoperatively (p<0.05,
3.6 fold). In contrast, our immunofluorescence results showed a decrease in the protein
level in DRG neurons during this time period; but a strong positive NMDA NR2B
immunoreactivety appeared in the satellite cells that surround the injured large-sized
neurons in L4 and L5 DRG neurons. In addition, immunofluorescence double labelling
revealed that DAPK1 and NMDA NR2B are co-localized in normal and injured DRG
neurons. In conclusion, the down-regulations of DAPK1 following sciatic nerve injury,
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along with other vital pro-apoptotic players promoting neuronal survival might shed
light on the mechanisms of peripheral nerve regeneration. The results also suggest that
NMDA NR2B might modulate neuropathic pain through satellite cells, and not through
neurons, 7 and 14 days after peripheral nerve injury.
Keywords: Neurobiology; death associated protein kinase 1; peripheral nerve injury;
dorsal root ganglion; pain; regeneration

	
  
	
  
	
  

viii	
  
	
  

Title and Abstract in Arabic
ﺩدﺭرﺍاﺳﺔ ﻣﺳﺗﻭوﻯى ﻭوﺟﻭوﺩد ﺍاﻟﺑﺭرﻭوﺗﻳﯾﻥن ﻛﻳﯾﻧﺎﺯز ) ( DAPK1ﻓﻲ ﺍاﻟﺧﻼﻳﯾﺎ ﺍاﻟﻌﺻﺑﻳﯾﺔ ﻟﻠﻌﻘﺩد ﺍاﻟﺟﺫذﺭرﻳﯾﺔ ﺍاﻟﻅظﻬﮭﺭرﻳﯾﺔ
ﺍاﻟﺳﻠﻳﯾﻣﺔ ﻭوﺑﻌﺩد ﺇإﺻﺎﺑﺔ ﺍاﻟﻌﺻﺏب ﺍاﻟﻁطﺭرﻓﻲ
ﻣﻠﺨﺺ ﺍاﻟﺒﺤﺚ
ﻳﯾﺭرﺗﺑﻁط ﺑﺭرﻭوﺗﻳﯾﻥن ﻛﻳﯾﻧﺎﺯز)  (DAPK1ﻋﺎﺩدﺓة ﺑﺎﻟﻣﻭوﺕت ﺍاﻟﺧﻠﻭوﻱي ﻭوﻳﯾﻣﻠﻙك ﻭوﻅظﻳﯾﻔﺔ ﺇإﻧﺯزﻳﯾﻣﻳﯾﺔ ﺍاﻟﻔﺳﻔﺭرﺓة )ﻛﻳﯾﻧﺎﺯز( ﻟﻛﻝل ﻣﻥن
ﺍاﻟﺳﻳﯾﺭرﻳﯾﻥن ﻭوﺍاﻟﺛﺭرﻳﯾﻭوﻧﻳﯾﻥن ،٬ﺧﺎﺿﻌﺔ ﻟﺗﺎ ﺛﻳﯾﺭر ﺍاﻟﻛﺎﻟﺳﻳﯾﻭوﻡم ﻛﺎﻟﻣﻭوﺩدﻭوﻟﻳﯾﻥن .ﺗﺩدﻋﻡم ﺩدﺭرﺍاﺳﺎﺕت ﻋﺩدﺓة ﺍاﻟﻳﯾﻭوﻡم ﺍاﻟﺩدﻭوﺭر ﺍاﻟﻛﺑﻳﯾﺭر ﺍاﻟﺫذﻱي
ﻳﯾﻠﻌﺑﻪﮫ ﻫﮬﮪھﺫذﺍا ﺍاﻟﺑﺭرﻭوﺗﻳﯾﻥن ﻓﻲ ﻣﺭرﺽض ﺍاﻟﺳﺭرﻁطﺎﻥن ﻭو ﻭوﺃأﻣﺭرﺍاﺽض ﺍاﻟﺟﻬﮭﺎﺯز ﺍاﻟﻌﺻﺑﻲ ﺍاﻟﻣﺭرﻛﺯزﻱي .ﺇإﻥن ﺩدﻭوﺭر ﻫﮬﮪھﺩدﺍا ﺍاﻟﺑﺭرﻭوﺗﻳﯾﻥن
ﻓﻲ ﺍاﻟﺟﻬﮭﺎﺯز ﺍاﻟﻌﺻﺑﻲ ﺍاﻟﻁطﺭرﻓﻲ ﻭو ﺍاﻷﻟﻡم ﺃأﻻﻋﺗﻼﻟﻲ ﻏﻳﯾﺭر ﻣﻌﺭرﻭوﻑف ﻋﻠﻰ ﺍاﻹﻁطﻼﻕق ﻭوﻟﻡم ﻳﯾﺳﺑﻕق ﺩدﺭرﺍاﺳﺗﻪﮫ ﺑﻌﺩد.
ﻧﻬﮭﺩدﻑف ﻓﻲ ﻫﮬﮪھﺫذﺍا ﺍاﻟﺑﺣﺙث ﺇإﻟﻲ ﺍاﺳﺗﻛﺷﺎﻑف ﻣﺧﺗﻠﻑف ﻣﺳﺎﺭرﺍاﺕت ﺍاﻟﺗﻌﺑﻳﯾﺭر ﺍاﻟﺟﻳﯾﻧﻲ ﻟﻠﻣﻭوﺭرﺛﺔ ) (DAPK1ﻭوﻋﻼﻗﺗﻬﮭﺎ
ﺑﻣﺧﺗﻠﻑف ﺍاﻟﺟﻳﯾﻧﺎﺕت ﺍاﻟﺗﻲ ﺗﻌﺭرﻑف ﺑﺗﺄﺛﻳﯾﺭرﻫﮬﮪھﺎ ﻓﻲ ﺍاﻟﻣﻭوﺕت ﺍاﻟﺧﻠﻭوﻱي ﺍاﻟﻣﺑﺭرﻣﺞ ﻭوﺍاﻟﺟﻳﯾﻧﺎﺕت ﺍاﻟﻣﺿﺎﺩدﺓة ﻟﻬﮭﺫذﺍا ﺍاﻷﺧﻳﯾﺭر
) .(p53, Bax, Akt, ERK5, p38 and NMDA-NR2Bﻛﻣﺎ ﻧﻬﮭﺩدﻑف ﺇإﻟﻰ ﺍاﻟﺗﺣﻘﻕق ﻣﻥن ﺇإﻣﻛﺎﻧﻳﯾﺔ ﺍاﻟﻌﻼﻗﺔ
ﺑﻳﯾﻥن DAPK1-NMDA NR2Bﻓﻲ ﺧﻼﻳﯾﺎ ﺍاﻟﻌﻘﺩد ﺍاﻟﺟﺫذﺭرﻳﯾﺔ ﺍاﻟﻅظﻬﮭﺭرﻳﯾﺔ ﺑﻌﺩد ﺳﺎﻋﺗﻳﯾﻥن 7 ،٬ﺃأﻳﯾﺎﻡم ﻭو 14ﻳﯾﻭوﻡم ﻣﻥن
ﻗﻁطﻊ ﻋﺻﺏب ﺍاﻟﻧﺳﻰ .ﺍاﺳﺗﺧﺩدﻣﻧﺎ ﻓﻲ ﻫﮬﮪھﺫذﻩه ﺍاﻟﺩدﺭرﺍاﺳﺔ ﺍاﻟﺑﺭرﻭوﺗﻳﯾﻥن ﺍاﻟﻣﺿﺎﺩد ﺇإﻟﻲ ) ( ATF3ﻛﻌﻼﻣﺔ ﻹﺻﺎﺑﺔ ﺍاﻟﺧﻼﻳﯾﺎ
ﺍاﻟﻌﺻﺑﻳﯾﺔ .ﺃأﺟﺭرﻳﯾﺕت ﻫﮬﮪھﺫذﻩه ﺍاﻟﺩدﺭرﺍاﺳﺔ

ﺑﺎﺳﺗﺧﺩدﺍاﻡم ﺗﻘﻧﻳﯾﺗﻲ ﺗﺣﻠﻳﯾﻝل ﺍاﻟﺗﻌﺑﻳﯾﺭر ﺍاﻟﺟﻳﯾﻧﻲ ) (qRT PCRﻭو ﺍاﻟﻛﻳﯾﻣﻳﯾﺎء

ﺍاﻟﻬﮭﻳﯾﺳﺗﻭوﻟﻭوﺟﻳﯾﺔ ﺍاﻟﻣﻧﺎﻋﻳﯾﺔ ) (Immunohistochemistryﻟﺗﻘﻳﯾﻳﯾﻡم ﺁآﺛﺎﺭر ﺇإﺻﺎﺑﺔ ﻋﺻﺏب ﺍاﻟﻧﺳﻰ.
ﻟﻘﺩد ﺃأﻅظﻬﮭﺭرﺕت ﻧﺗﺎﺋﺞ ﻫﮬﮪھﺫذﺍا ﺍاﻟﺑﺣﺙث ﻭوﺟﻭوﺩد ﻧﺳﺦ  RNAﺍاﻟﺭرﺳﻭوﻝل ﻟﻣﻭوﺭرﺛﺔ  DAPK1ﻭو ﺗﺭرﺟﻣﺗﻬﮭﺎ ﺇإﻟﻰ
ﺑﺭرﻭوﺗﻳﯾﻥن ﻓﻲ ﺧﻼﻳﯾﺎ ﺍاﻟﻌﻘﺩد ﺍاﻟﺟﺫذﺭرﻳﯾﺔ ﺍاﻟﻅظﻬﮭﺭرﻳﯾﺔ ﺍاﻟﻁطﺑﻳﯾﻌﻳﯾﺔ ﺍاﻟﺳﻠﻳﯾﻣﺔ .ﻟﻘﺩد ﺗﻡم ﻣﻼﺣﻅظﺔ ﺍاﺭرﺗﻔﺎﻉع ﻣﻌﺗﺑﺭر ﻓﻲ ﻧﺳﺦ
 RNAﺍاﻟﺭرﺳﻭوﻝل ﻟﻣﻭوﺭرﺛﺔ ﺑﺄﻛﺛﺭر ﻣﻥن ﺍاﻟﺿﻌﻑف )ﺃأﺿﻌﺎﻑف(p<0.05, 2.2

ﻓﻲ ﺍاﻟﺧﻼﻳﯾﺎ ﺍاﻟﻌﺻﺑﻳﯾﺔ ﻟﻠﻌﻘﺩد

ﺍاﻟﺟﺫذﺭرﻳﯾﺔ ﺍاﻟﻅظﻬﮭﺭرﻳﯾﺔ ﻟﻠﻌﺻﺑﻭوﻥن ﺍاﻟﻅظﻬﮭﺭرﻱي ﺍاﻟﺭرﺍاﺑﻊ ﻭو ﺍاﻟﺧﺎﻣﺱس ﺍاﻟﻣﻭوﺟﻭوﺩدﺓة ﺟﻬﮭﺔ ﺍاﻟﻘﻁطﻊ ﺑﺎﻟﻣﻘﺎﺭرﻧﺔ ﻣﻊ ﺍاﻟﺟﻬﮭﺔ
ﺍاﻟﺳﻠﻳﯾﻣﺔ.ﻏﻳﯾﺭر ﺃأﻥن ﺑﻌﺩد  7ﺃأﻳﯾﺎﻡم ﻣﻥن ﻗﻁطﻊ ﻋﺻﺏب ﺍاﻟﻧﺳﻰ ،٬ﺷﺎﻫﮬﮪھﺩدﻧﺎ ﺇإﻧﺧﻔﺎﺽض ﻣﻌﺗﺑﺭر ﻓﻲ ﺍاﻟﺗﻌﺑﻳﯾﺭر ﺍاﻟﻭوﺭرﺛﻲ ﻟﻣﻭوﺭرﺛﺔ
)  (DAPK1ﺍاﻟﺫذﻱي ﺑﻠﻎ ﺃأﻗﺻﺎﻩه ﺑﻌﺩد  14ﻳﯾﻭوﻡم ﻣﻥن ﻹﺻﺎﺑﺔ.
ﻛﻣﺎ ﺟﺎءﺕت ﻧﺗﺎﺋﺞ ﺗﻘﻧﻳﯾﺔ ﺍاﻟﻛﻳﯾﻣﻳﯾﺎء ﺍاﻟﻬﮭﺳﺗﻭوﻟﻭوﺟﻳﯾﺔ ﺍاﻟﻣﻧﺎﻋﻳﯾﺔ ﻣﺷﺎﺑﻬﮭﺔ ﻟﻧﺗﺎﺋﺞ ﺗﺣﻠﻳﯾﻝل ﺍاﻟﺗﻌﺑﻳﯾﺭر ﺍاﻟﺟﻳﯾﻧﻲ ﺣﻳﯾﺙث
ﺃأﻅظﻬﮭﺭرﺕت ﻣﻌﻅظﻡم ﺍاﻟﺧﻼﻳﯾﺎ ﺇإﻳﯾﺟﺎﺑﻳﯾﺔ ) DAPK1ﺇإﻳﯾﺟﺎﺑﻳﯾﺔ ﺃأﻳﯾﺿﺎ ﻓﻲ ) (ATF3ﺑﻌﺩد  7ﺍاﻳﯾﺎﻡم ﻣﻥن ﻗﻁطﻊ ﻋﺻﺏب ﺍاﻟﻧﺳﻰ
) ،٬(%76.11ﻓﻲ ﺣﻳﯾﻥن ﻗﻠﺕت ﻫﮬﮪھﺫذﻩه ﺍاﻟﻧﺳﺑﺔ ﺇإﻟﻲ ) (% 53.89ﺑﻌﺩد  14ﻳﯾﻭوﻡم ﻣﻥن ﺍاﻟﻘﻁطﻊ .ﻭوﻣﻥن ﺍاﻟﻣﺛﻳﯾﺭر ﻟﻼﻫﮬﮪھﺗﻣﺎﻡم
ﺃأﻧﻪﮫ ﻗﺩد ﺟﺎء ﺍاﻟﺗﻌﺑﻳﯾﺭر ﺍاﻟﺟﻳﯾﻧﻲ ﻟﻛﻝل ﻣﻥن ﺍاﻟﻣﻭوﺭرﺛﺗﻳﯾﻧﻥن  p53ﻭو Baxﻣﻧﺧﻔﺿﺎ ﺑﻌﺩد 7ﺍاﻳﯾﺎﻡم ﻣﻥن ﺍاﻹﺻﺎﺑﺔ ﻭوﻫﮬﮪھﺫذﺍا
ﻳﯾﺗﻧﺎﺳﺏب ﻁطﺭرﺩدﻳﯾﺎ ﻣﻊ ﺍاﻧﺧﻔﺎﺽض ﺍاﻟﺗﻌﺑﻳﯾﺭر ﺍاﻟﻣﻭوﺭرﺛﻲ ﻝل  DAPK1ﻓﻲ ﺍاﻟﺧﻼﻳﯾﺎ ﺍاﻟﻌﺻﺑﻳﯾﺔ ﺍاﻟﻣﺻﺎﺑﺔ ﺍاﻟﻣﻭوﺟﻭوﺩدﺓة ﻓﻲ
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ﺍاﻟﻌﻘﺩد ﺍاﻟﺟﺫذﺭرﻳﯾﺔ ﺍاﻟﻅظﻬﮭﺭرﻳﯾﺔ .ﻓﻲ ﺣﻳﯾﻥن ﺃأﻅظﻬﮭﺭرﺕت ﺍاﻟﻧﺗﺎﺋﺞ ﺃأﻥن ﺇإﺻﺎﺑﺔ ﻋﺻﺏب ﺍاﻟﻧﺳﻰ ﻟﻡم ﺗﺄﺛﺭر ﺑﺷﻛﻝل ﻣﻌﺗﺑﺭر ﻋﻠﻰ
ﺍاﻟﺗﻌﺑﻳﯾﺭر ﺍاﻟﺟﻳﯾﻧﻲ ﻣﻥن  p38 ،٬ERK5ﻭو Aktﺧﻼﻝل ﻣﺧﺗﻠﻑف ﺍاﻷﺯزﻣﻧﺔ ﺍاﻟﻣﺩدﺭرﻭوﺳﺔ ﻓﻲ ﻫﮬﮪھﺫذﺍا ﺍاﻟﺑﺣﺙث .ﻭوﻣﻥن ﺟﺎﻧﺏب
ﺃأﺧﺭر  ،٬ﻋﻼﻭوﺓة ﻋﻠﻰ ﺍاﺭرﺗﻔﺎﻉع  RNAﺍاﻟﺭرﺳﻭوﻝل ﻟﻠﻣﻭوﺭرﺛﺔ  NMDA NR2Bﺑﻌﺩد  7ﺃأﻳﯾﺎﻡم ﺑﻌﺩد ﺇإﺻﺎﺑﺔ ﻋﺻﺏب
ﺍاﻟﻧﺳﻰ ﻭوﻣﻼﺣﻅظﺔ ﺃأﺳﺗﻣﺭرﺍاﻩه ﻓﻲ ﺍاﻹﺭرﺗﻔﺎﻉع ﺣﺗﻰ ﺍاﻟﻳﯾﻭوﻡم ) 14ﺃأﺿﻌﺎﻑف  ،٬(p<0.05, 3.6ﺇإﻻ ﺃأﻥن ﻧﺗﺎﺋﺞ
ﺍاﻟﻛﻳﯾﻣﻳﯾﺎء ﺍاﻟﻬﮭﻳﯾﺳﺗﻭوﻟﻭوﺟﻳﯾﺔ ﺍاﻟﻣﻧﺎﻋﻳﯾﺔ ﺃأﻅظﻬﮭﺭرﺕت ﻷﻭوﻝل ﻣﺭرﺓة ﻣﺎ ﻳﯾﻭوﺿﺢ ﺍاﻧﺧﻔﺎﺽض ﻣﺳﺗﻭوﻯى ﺑﺭرﻭوﺗﻳﯾﻥن ﺍاﻟﻣﺳﺗﻘﺑﻝل
 NMDA NR2Bﻓﻲ ﺍاﻟﺧﻼﻳﯾﺎ ﺍاﻟﻌﺻﺑﻳﯾﺔ ﻟﻠﻌﻘﺩد ﺍاﻟﺟﺫذﺭرﻳﯾﺔ ﺍاﻟﻅظﻬﮭﺭرﻳﯾﺔ ﻓﻲ ﺍاﻟﻔﺗﺭرﺓة ﺍاﻟﺯزﻣﻧﻳﯾﺔ ﺍاﻟﻣﺩدﺭرﻭوﺳﺔ ﻭوﺍاﺭرﺗﻔﺎﻋﻪﮫ ﻓﻲ
ﺍاﻟﺧﻼﻳﯾﺎ ﺍاﻟﺳﺎﺗﻠﺔ ﺍاﻟﻣﺣﻳﯾﻁطﺔ ﺑﺎﻟﺧﻼﻳﯾﺎ ﺍاﻟﻌﺻﺑﻳﯾﺔ ﻛﺑﻳﯾﺭرﺓة ﺍاﻟﺣﺟﻡم ﺍاﻟﻣﺻﺎﺑﺔ ﻓﻲ ﻛﻝل ﻣﻥن ﺍاﻟﻌﺻﺑﻭوﻥن ﺍاﻟﻅظﻬﮭﺭرﻱي ﺍاﻟﺭرﺍاﺑﻊ ﻭو
ﺍاﻟﺧﺎﻣﺱس ﻓﻲ ﺍاﻟﺧﻼﻳﯾﺎ ﺍاﻟﻌﺻﺑﻳﯾﺔ ﻟﻠﻌﻘﺩد ﺍاﻟﺟﺫذﺭرﻳﯾﺔ ﺍاﻟﻅظﻬﮭﺭرﻳﯾﺔ .ﺑﺎﻹﺿﺎﻓﺔ ﺇإﻟﻰ ﺫذﻟﻙك ،٬ﻛﺷﻔﺕت ﻧﺗﺎﺋﺞ ﺍاﻟﺗﺄﻟﻕق ﺍاﻟﻣﻧﺎﻋﻲ
ﺍاﻟﻣﺯزﺩدﻭوﺝج ﺍاﻟﺗﺯزﺍاﻣﻥن ﻓﻲ ﺗﻭوﺍاﺟﺩد ﺍاﻟﺑﺭرﻭوﺗﻳﯾﻧﻳﯾﻥن  DAPK1ﻭوﺍاﻟﺑﺭرﻭوﺗﻳﯾﻥن  NMDA NR2Bﻓﻲ ﺍاﻟﺧﻼﻳﯾﺎ ﺍاﻟﻌﺻﺑﻳﯾﺔ
ﺍاﻟﻣﺻﺎﺑﺔ ﻭو ﺍاﻟﺳﻠﻳﯾﻣﺔ ﻟﻠﻌﻘﺩد ﺍاﻟﺟﺫذﺭرﻳﯾﺔ ﺍاﻟﻅظﻬﮭﺭرﻳﯾﺔ.
ﻓﻲ ﺍاﻟﺧﺗﺎﻡم ،٬ﺇإﻥن ﺍاﻟﺗﺭرﺍاﺟﻊ ﻓﻲ ﻣﺳﺗﻭوﻯى  DAPK1ﻛﻧﺗﻳﯾﺟﺔ ﻻﺻﺎﺑﺔ ﻋﺻﺏب ﺍاﻟﻧﺳﻰ ﻭوﺗﺯزﺍاﻣﻥن ﻫﮬﮪھﺫذﺍا
ﺍاﻹﻧﺧﻔﺎﺽض ﻣﻊ ﻭوﺳﺎﺋﻁط ﺍاﻟﻣﻭوﺕت ﺍاﻟﺧﻠﻭوﻱي ﺍاﻟﻣﺑﺭرﻣﺞ ﻟﺗﺳﻠﻁط ﺍاﻟﺿﻭوء ﻋﻠﻰ ﺁآﻟﻳﯾﺎﺕت ﻗﺩد ﻳﯾﻛﻭوﻥن ﻟﻬﮭﺎ ﺗﺄﺛﻳﯾﺭر ﻓﻲ ﺗﺟﺩدﺩد
ﺍاﻷﻋﺻﺎﺏب ﺍاﻟﻁطﺭرﻓﻳﯾﺔ .ﻛﻣﺎ ﺗﺄﺗﻲ ﻧﺗﺎﺋﺞ ﻫﮬﮪھﺫذﺍا ﺍاﻟﺑﺣﺙث ﻣﻭوﺿﺣﺔ ﺍاﻣﻛﺎﻧﻳﯾﺔ ﺃأﻥن ﻳﯾﻠﻌﺏب  NMDA NR2Bﺩدﻭوﺭر ﻓﻲ
ﺗﻌﺩدﻳﯾﻝل ﺍاﻷﻟﻡم ﺍاﻹﻋﺗﻼﻟﻲ ﻣﻥن ﺧﻼﻝل ﻭوﺟﻭوﺩدﻩه ﻓﻲ ﺍاﻟﺧﻼﻳﯾﺎ ﺍاﻟﺳﺎﺗﻠﺔ ﻭو ﻟﻳﯾﺱس ﺍاﻟﻌﺻﺑﻳﯾﺔ ﺑﻌﺩد  7ﻭو  14ﻳﯾﻭوﻡم ﻣﻥن ﺇإﺻﺎﺑﺔ
ﺍاﻟﺟﻬﮭﺎﺯز ﺍاﻟﻌﺻﺑﻲ ﺍاﻟﻁطﺭرﻓﻲ.
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CHAPTER 1: INTRODUCTION
1.1 Overview
Death associated protein kinase1 (DAPK1) is a novel calcium/calmodulin (Ca2+/CaM).
It regulates the serine/threonine kinase that plays an important role in a wide variety of
signal transduction pathways such as apoptosis, autophagy, and immune responses
induced by various stimuli in different cell systems (Cohen et al., 1997, 1999; Deiss et
al., 1995; Inbal et al., 1997; Jang et al., 2002; Pelled et al., 2002; Raveh et al., 2001;
Yamamoto et al., 2002). These studies revealed that DAPK1 is a positive mediator of
program cell death signals including interferon-α, tumor necrosis factor α (TNFα),
transforming growth factor (TGFβ), Fas and detachment from the extracellular matrix
(Cohen et al., 1997, 1999; Deiss et al., 1995; Inbal et al., 1997; Jang et al., 2002; Pelled
et al., 2002; Raveh et al., 2001; Yamamoto et al., 2002), as well as oncogenes such as cMyc and tumor protein p53, E2F transcription factor 1, and ceramide (Inbal et al., 2002;
Lin et al., 2010; Schumacher et al., 2002).
Overexpression of the DAPK1 death domain has been reported to protect cells
from death by TNFα, TGFβ and Fas (Cohen et al., 1999; Jang et al., 2002). Furthermore,
it has been well documented that DAPK1 participates in autophagosome formation,
mitochondrial

depolarization

and

permeabilisation,

caspases

activation,

DNA

fragmentation, cytoskeleton reorganization and membrane blebbing (Bialik and Kimchi,
2004).
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In the central nervous system (CNS), several investigators have found that
DAPK1 mRNA is particularly abundant in the adult brain (Bialik and Kimchi, 2004),
with protein expression pattern limited to cortical areas, hippocampus, the olfactory bulb
and cerebellar Purkinje cells (Sakagami and Kondo, 1997; Tian et al., 2003). It is
already established that DAPK1 is a key player in several modes of neuronal
death/injury and has been implicated in brain damage in stroke, epilepsy, Alzheimer's
disease (AD) and neuronal death in cerebral ischemia (Fujita and Yamashita, 2014). In
addition, Schumacher et al. (2002) demonstrated that DAPK1 may have a role in both
neuronal developments as well as in recovery from injury, as an up-regulation of
DAPK1 has been reported in the affected hippocampus 7 days after ischemic injury.
Furthermore, DAPK1 has been suggested to have other functional roles such as
regulating exocytosis of neurotransmitter release by phosphorylation of syntaxin-1 (Tian
et al., 2003) and protecting neurons during development or recovery from hypoxicischemic injury (Schumacher et al., 2002). The absence of DAPK1 has been shown to
protect neurons from a wide variety of acute toxic insults (Fujita and Yamashita, 2014).
DAPK1 has also been shown to function as a mediator of multi types of stress signals
induced by deprivation of neuronal cells from Netrin-1, and stimulation of N-methyl-Daspartate (NMDA) receptors in cerebral ischemia (Bialik and Kimchi, 2004; Tu et al.,
2010). Tu et al. (2010) have found that DAPK1 physically and functionally interacts
with the NMDA receptor NR2B subunit and this interaction leads to severe stroke
neuronal damage.
NMDA NR2B receptor subunit constitutes a major subtype of glutamate receptor
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at extrasynaptic sites that evokes multiple intracellular catabolic processes responsible
for neuronal death (Mathur et al., 2009; Tu et al., 2010). Knockdown of DAPK1 or
blocking DAPK1- NMDA NR2B interaction protected mice against cerebral ischemic
damage and is considered to be a possible treatment for stroke (Tu et al., 2010). Along
with its role in neuronal death, accumulating evidence implicates the importance of
NMDA NR2B subunit–containing receptors in facilitating nociception (Boyce et al.,
1999; Taniguchi et al., 1997) and suggested to be responsible for the development of
chronic pain (Nagy et al., 2004). NR2B subunit has a relatively restricted distribution in
nociceptive transmission and pain regulatory pathways such as in the forebrain (Laurie
et al., 1997) and in the superficial dorsal horn of the spinal cord (Boyce et al., 1999;
Nagy et al., 2004).

1.2 Statement of the Problem
All previous studies with regards to DAPK1 as a novel protein were carried out in the
CNS. The presence of DAPK1 in the PNS and its role in peripheral nerve regeneration
remains completely unexplored. Following an initial pilot study carried out in our lab at
UAEU DAPK1 was detected in normal DRG neurons. It is, therefore, hypothesized that
DAPK1 (i) along with other pro-apoptotic factors might be involved in the injury
response mechanism leading up to successful peripheral nerve regeneration (ii) might
have a significant contribution to intrinsic regulation of neuropathic pain after peripheral
nerve injury through its relation with NMDA NR2B in DRG neurons.
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1.3 Relevant Literature
1.3.1 Cellular and Molecular Changes after Peripheral Nerve Injury
Peripheral nervous system (PNS) injuries are common around the world. They affect
more than one million people annually worldwide and account for incalculable health
care costs. There are wide varieties of peripheral nerve injuries, which may result from
neurological diseases, lacerations, simple nerve compression, crush, ischemia, traction
and vibration. The outcome of a nerve injury may vary according to the etiology of the
trauma. PNS injuries may lead to partial or total loss of motor, sensory and autonomic
functions and have a marked impact on the quality of life of patients and economic
relevance to society, with no easily available formula for successful treatment
(Zochodne, 2008).
Research on treatment of nervous system injuries has been a long-standing goal
of the neuroscience and medical community. Howell and Huber in 1893 carried the first
controlled study of experimental injury and subsequent repair using dogs. This was
followed by a similar study by Sherren in 1908 (Zachary and Holmes, 1946). Over the
past century, numerous investigations have been carried out on peripheral nerve injury to
reveal intracellular signaling processes and its regeneration response. However, a
comprehensive understanding of the nature of the PNS injury response is yet to be
attained. While neurons in the CNS have a limited capacity for regrowth after injury,
neurons in the PNS can readily regenerate following injury. It has become clear that
ability of the nerve to regenerate has a molecular basis (Makwana and Raivich, 2005).
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Injury to the PNS initiates a cascade of degenerative cellular and molecular
changes at the site of injury. Zochodne in his book, Neurobiology of Peripheral Nerve
Regeneration in 2008, described the molecular details of how repair is achieved through
degeneration and regeneration of severed axons followed by re-innervation of target
tissues. After injury and degeneration, nerve fibers regrow from the proximal stump to
the distal. Only if all these molecular steps are satisfactorily completed, will the injured
nerve be able to regain their lost functionality. To achieve successful re-innervation,
several key processes need to be precisely regulated and coordinated. It is worth
knowing that the intrinsic growth capacity of an injured neuron is influenced by the
external environment (Zochodne, 2008).
In this section, we will address the current neurobiology of the molecular
mechanisms involved in both nerve degeneration and regeneration, which may help in
achieving successful nerve regrowth and functional recovery. We will emphasize the
current understanding of early molecular changes associated with nerve injury,
degeneration nerve processes, non-neuronal cell roles, the subsequent activation of
transcription factors, cytokines, neuropeptides, neurotrophic factors and other induced
molecules that have been reported to play an important role after nerve injury.
1.3.1.1 PNS Anatomy
The nervous system comprises both the CNS and the PNS. The CNS originally develops
from the neural tube, whereas the PNS develops from parts of the neural tube and neural
crest cells during neurogenesis. Anatomically, the human and mammalian PNS consists
of 12 cranial nerves and 31 pairs of spinal nerves linking the brain and the spinal cord to
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the peripheral tissues. Ten out of 12 cranial nerves originate from the brain stem and
mainly control the function of the anatomic structure of the head. The spinal nerves arise
from the spinal cord and control the functions of the rest of the body (Hanani, 2005;
Price, 1985, Lawson, 1992; Zochodne, 2008).
In the PNS, multiple axons are bound together by sheaths of connective tissue to
form a nerve. Schwann cells enclose the axons either with a multi-layer myelin sheath,
or with a simpler ensheathing arrangement. Less than half of the nerves are enclosed
within myelin sheaths. The myelin sheath is discontinuous longitudinally by 1 micron
(µm) length gaps called nodes of Ranvier at which the axon membrane conduct
electrical potentials that are transmitted through the axon (Berta et al., 2008;
Renganathan et al., 2001). Dendrites are numerous short processes around the soma that
carry the action potential. Neurons can communicate with other neurons or muscle cells
or glands across a junction between cells called a synapse.
PNS neurons can be classified, according to their shapes, into pseudounipolar,
bipolar, or multipolar. In terms of function, PNS neurons are divided into a somatic and
a visceral part. The somatic part consists of the nerves that innervate the skin, muscles,
and joints. While the visceral part, also known as the autonomic nervous system,
contains neurons that innervate the internal organs, glands and blood vessels. A typical
peripheral nerve is composed of efferent motor axons originating from spinal motor
neurons and afferent sensory axons originating from dorsal root ganglion (DRG)
neurons.
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The DRG conveys sensory information from the periphery to the CNS. DRG has
a special location in the nervous system, as it is located in between the dorsal root and
the spinal nerve. DRG neurons have two branches originating from a pseudounipolar
neuron. They consist of a peripheral branch that innervates sensory targets and has the
ability to regenerate when injured, and a central branch that extends into the spinal cord
and relays information to the CNS but lacks the ability to regenerate following injury.
Therefore, an injury to the peripheral nerve will affect both motor and sensory functions
and induce retrograde reactions in both spinal cord and DRGs neuron. The PNS is not
protected by bone or by the blood-brain barrier as the case in CNS, leaving it exposed to
toxins and mechanical injuries (Hanani, 2005; Price, 1985; Lawson, 1992; Zochodne,
2008).
The basic subdivisions of DRG cells are large light (LL) A-cells and small dark
(SD) B-cells intermixed within the ganglion (Duce and Keen, 1977; Kalina and Bubis,
1968; Kalina and Wolman, 1970; Lawson, 1979; Lawson et al., 1974; Novikoff et al.,
1971; Spater et al., 1978) based on size of the perikarya or the morphology and
distribution of Nissl bodies (Clark, 1926; Andres, 1961) or the Golgi apparatus (Duce
and Keen, 1977). Rambourg et al. (1983) examined the lumbar dorsal root ganglia of
rats by electron microscopy and identified three types of ganglion cells according to
their size (A, B, C) from large to medium respectively. These were then subdivided
further into six subtypes (A1, A2, A3, B1, B2 and C) based on the arrangement and
three-dimensional organization of both Nissl bodies and Golgi apparatus in the perikarya
(Figure 1).
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Figure 1: Illustrating the characteristic features of six types of neurons in rat lumber DRG
A 1, A2 are large neuron with Nissl bodies evenly distributed throughout the cytoplasm and
separated from each other by narrow spaces, wide strands of neuroplasm. A3 smaller than A1, A2
and displayed Nissl bodies widely dispersed throughout the perikaryon and a well-developed Golgi
apparatus. B1, Small neuron with curved Golgi bodies arranged in a perinuclear ring and Nissl bodies
located mainly in an outer cytoplasmic zone B2: Small neuron showing Golgi apparatus and Nissl
bodies evenly distributed throughout the perikaryon, the Golgi apparatus forms a ring separated from
the nucleus by mitochondria and smooth ER. C: smallest of all the ganglion cells with poor present
of Nissl Bodies and a few flattened ER cisternae arranged in a parallel manner (Rambourg et al.,
1983).
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The large light neuron, the A type is also further classified as Aα, Aβ, and Aδ
(myelinated, fast conducting). Moreover, the axons of small dark neurons are also
classified as C fibers (non-myelinated, slow conducting) (Millan, 1999; Tandrup, 1993a)
(Figure 2 a-c). Many of the small diameter neurons are nociceptive and they function
mainly in thermo- and mechanoreception. They are either peptidergic or nonpeptidergic. Peptidergic small dark neurons express peptides such as endothelin 1 (ET1),
galanin, nociceptin, somatostatin, substance P (SP), pituitary adenylate cyclase
activating polypeptide (PACAP), and vasoactive intestinal polypeptide (VIP). The
majority of these peptidergic small neurons are identified to be isolectin B4 (IB4)negative neurons and depend on nerve growth factor (NGF) for survival during postnatal
development (Molliver et al., 1997; Hokfelt et al 1994) whereas, non-peptidergic
neurons are IB4-positive neurons and depend on glial-derived neurotrophic factor
(GDNF) for survival (Fang et al., 2005; Stucky and Lewin, 1999).
On the other hand, LL neurons serve as mechanoreceptors and proprioceptors
(Lawson, 1992) and can be identified based on the expression of the heavy chain
neurofilament, NF200. They also express trkA, trkC and p75 neurotrophin receptor
(Devor et al., 1984; Kai-Kai, 1989; Kovalsky et al., 2009; Maher et al., 2009;
Wickenden et al., 2009) (Figure 2 a-c). Currently, the DRG neuron has become the main
foucs to understand the mysteries that lead to successful neuronal regeneration and the
control of neuropathic pain. Neuropathic pain can be defined as a chronic pain caused by
an injury in the somatosensory system. After PNS injury, numerous changes have been
detected in primary sensory neurons thought to be the main source for both regeneration
and neuropathic pain.
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Figure 2: Anatomy of the somatosensory system, neuron cell bodies in the DRG.

(A) DRG location outside the spinal cord. (B) Trigeminal Somatosensory neurons with both central
and peripheral targets. (C) Classification of Somatosensory neurons into small, medium and large
diameter neurons based on their cell bodies size and myelination degree (Le Pichon et al., 2009).
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1.3.1.2 Classification of Nerve Injuries
A peripheral nerve injury occurs when a nerve is compressed, crushed or severed. The
severity of nerve injuries varies from minor, such as digital nerve injury to major, such
as brachial plexus injury. The cellular changes after injury and their outcomes are
determined by the amount of nerve damage and the degree of connective-tissue sheaths,
the site of the lesion, the health and age of the patient (Hall, 2005). While nerve repair
after injury in children is usually associated with full functional recovery, but that in
adults and the elderly may experience slow or absent functional recovery. It was
reported that more than half of the individuals over the age of 50 were not able to
achieve any functional recovery after nerve repair following injury (Verdú et al., 2000).
Peripheral nerve injury is common and often causes long lasting disability, which
may lead to severe consequences. It may cause pain, paralyze muscles or lead of
adequate sensory feedback from nerve receptors in the target organs such as skin, joints
and muscles (Lundborg and Rosén, 2007). It may lead to loss of touch perception,
impaired or disturbed temperature perception and cold sensitivity.
Classification of nerve injury was described by Seddon in 1943 and by
Sunderland in 1951 (Seddon, 1950; Sunderland, 1978). Seddon classified the severity of
nerve injury into three major groups ranging from least to most severe: neuropraxia,
axonotmesis and neurotmesis (Seddon, 1950). In the mild injury “neuropraxia”, the
nerve remains intact but the signalling ability is damaged, where there is a physiological
block within the axons. In “neuropraxia” there is no histological change in the axons or
myelin sheath and full recovery is expected within a few weeks.
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Axonotmesis is a moderate injury and it refers to the disruption of several axons
and myelin sheath but without significant damage to the connective tissue layers
(Seddon et al., 1943). It is an anatomical interruption of the axons with preservation of
the perineurium and epineurium and it may be the result of a crush injury or neuroma
formation. In this type of injury, recovery is expected within 4-6 weeks (Seddon, 1954).
The most severe type of injury is neurotmesis, where axon, myelin sheath and the
connective tissue elements are disturbed. Unfortunately, no functional recovery is
possible without surgical intervention.
Sunderland classified the nerve injury in 1951 further into five different classes
where first-degree injuries are equivalent to neuropraxia. 2nd, 3rd and 4th degree injuries
correspond to axonotmesis and 5th degree injuries are equivalent to neurotmesis.
Sunderland's classification requires histological analysis of the injured nerve (Birch,
2005; Sunderland, 1978).
Experimental sciatic nerve (SN) injury is a common approach that has been used
to study the patterns of peripheral nerve regeneration. The three most popular methods
are complete SN transection which is similar to neurotmesis, crush injury which is
similar to axonotmesis and chronic constrictive injury (CCI) which is similar to
neuropraxia (Chen et al., 2006).
1.3.1.3 Factors Influencing Neuronal Injury Response
CNS and PNS vary in their anatomy, physiology and regeneration ability after injury.
Injured neurons in the mammalian PNS can regenerate and restore function but this
requires several intrinsic axonal growth capabilities (Makwana and Raivich, 2005) and
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extrinsic environmental support. In contrast to PNS damage, injuries to the CNS (brain
and spinal cord) are almost always irreversible and would lead to permanent loss of
function.
Injury to the peripheral nerve results in a sequence of molecular and cellular
responses and a multitude of changes within an organism, including motor dysfunction,
pain and associated cognitive and emotional comorbidities. When a peripheral nerve is
axotomized, there is an immediate injury response in the area supplied by that nerve
such as paralysis of the muscles and loss of sensation. PNS injury response could result
in both neuronal survival and regeneration or neuronal cell death (Lundborg, 2000).
Neuronal cell death might be an outcome of alterations in electrical activity, release of
neurotoxic inflammatory products and loss of target derived neurotrophic support
(Ambron and Walters, 1996; Fu and Gordon, 1997).
Adult peripheral neuron regeneration has been demonstrated in numerous studies
both in vivo and in vitro (André et al., 2003; Jacob and McQuarrie, 1993; Lankford et
al., 1998; Smith and Skene, 1997; Tanaka et al., 1992). On the other hand, many
experimental studies have also shown the permanent loss of primary sensory neurons
after injury (Schmalbruch, 1987; Ygge, 1989). It has been proven that proximal injuries
produce more marked neuronal loss than distal injuries. Experimentally, cutting the
nerve in the proximal thigh resulted in an average neuronal loss of 27% whereas cutting
it at mid-thigh level resulted in a 16-23% loss (Arvidsson et al., 1986; Schmalbruch,
1987; Ygge, 1989) and cutting the proximal calf caused just a 7% drop in numbers
(Ygge, 1989).
	
  
	
  
	
  

14	
  

	
  

In the last two decades, observation of DNA fragmentation in vivo confirmed the
above results (Groves et al., 1997; McKay Hart et al., 2002; Oliveira et al., 1997) and
the extent of the loss ranges from 7 to 51% (Groves et al., 1997; Jivan et al., 2006; Liss
et al., 1994, 1996; Ma et al., 2003; Rich et al., 1989; Tandrup, 1993b). Neuronal cell
death rate depends on many factors such as proximity of axotomy to the DRG (Ygge,
1989), the age of the animal (Bahadori et al., 2001; Kerezoudi et al., 1995), axon
diameter , length of the distal segment and the species used (Kline et al., 1964a, 1964b).
All these factors have been shown to influence neuronal response, which may lead to
neuronal death or high regenerative capacity.
Injury responses vary in different experimental model; for example loss of the
axoplasmic cytoskeleton in small laboratory rodents begins one to two days after injury
while it occurs within seven days in humans, these variations being approximately
directly proportional to the size of the animal (Glass et al., 2002). Therefore, it is
important to consider which animal model to use when analysing and integrating data as
timing of injury response differs between species.
1.3.1.4 PNS Cellular Changes after Injury
PNS injury leads to a series of changes initiated both proximally and distally to the
lesion site. Sensory neurons switch from a transmitting mode to a regrowth mode.
Chromatolysis, where the cell body undergoes a sequence of changes characterized by
swelling of the soma, nucleolar enlargement, displacement of the nucleus to the
periphery and dissolution of Nissl bodies have been seen as a consequence of neuron
injury (Lieberman, 1971; Kreutzberg, 1995).
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Other changes including increases in cytoplasmic acid phosphatase and smooth
endoplasmic reticulum with hypertrophy of Golgi apparatus. Neuron cell body swelling
is due to tissue edema and exudation of acid mucopolysaccharides; it can be noted
within one hour after injury and this soma enlargement may persist for 10 to 20 days
after injury. Within 24 to 48 hours after injury, axon thickening is evident histologically
(Brattgård and Thulin, 1965; Ducker et al., 1969).
Biochemical changes in the neurons of the DRG following injury are also
associated with a strong increase in cellular metabolism and protein synthesis, changes
in gene transcription, changes in translation, stability, or subcellular localization of
translated proteins and post-translational modification of proteins (Bhave and Gereau,
2004; Caroni, 1998; Hall, 2001; Makwana and Raivich, 2005). It has been reported that
local presynaptic processes may detach from the neuron soma and its dendritic tree.
Interestingly, at the proximal stump axon sprouts can be noticed within hours of injury,
and if the regenerative phenotype is successfully initiated, axon regrowth will start in
days (Hall, 2005).
Generally, after nerve injury, the distal stump triggers major damage while the
proximal stump is often only minimally damaged and can further regenerate towards the
distal end. A distal growth cone can be seen that seeks out connections with the
degenerated distal fiber. The proximal PNS injured nerve undergoes a sprouting process
after injury (Bonilla et al., 2002) while the distal portion undergoes a stereotypical
reaction, some simultaneous, others consecutive and are collectively called Wallerian
degeneration (WD). Augustus Waller originally described WD in 1850 during his study
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of the morphological consequence of cutting frogs’ peripheral nerves. It is a
degenerative cellular process initiated throughout the distal nerve portion and within a
small reactive zone at the tip of the proximal stump of the axons after a traumatic injury
(Koeppen, 2004; Pearce, 2000).
The type of nerve fiber affected (motor or sensory neurons, myelinated or
unmyelinated fibers) and the type and severity of injury (from a slight crush to complete
transection), leads to cascades of axonal degeneration events that differ in time and
damage severity (Coleman, 2005) or demyelination (Nave and Trapp, 2008; De Vos et
al., 2008). WD proceeds after complete nerve transection and leads to connective tissue
sheath damage, while this damage is absent following nerve crush injuries (Rotshenker,
2011).
Axon degeneration is a final common pathway identified not only after a
traumatic nerve injury, but also in many neurodegenerative diseases such as Parkinson`s
and Alzheimer`s diseases and in demyelinating diseases like multiple sclerosis
(Coleman, 2005; Coleman and Freeman, 2010). Intrinsic degenerative pathways that are
triggered during WD are not correlated to cellular apoptosis (Finn et al., 2000).
Wallerian Degenration process begins within hours of injury with fragmentation of
cytoskeleton proteins (microtubules and neurofilaments) and degradation of the
axoplasm and axolemma in the distal nerve segment due to activation of ubiquitinproteasome system (UPS) and calcium-dependent proteases, respectively (Vargas and
Barres, 2007). Within hours following injury, the ends of the severed axons are sealed,
followed by myelin and axonal break up to form ellipsoids.
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The nerve injury interferes with the retrograde flow of signals from the normal
innervation target. By 48 to 96 hours post injury, axonal continuity is lost and
conduction of impulses no longer occurs. This may lead to the emergence of a negative,
denervation signal, following the disconnection. This injury-induced discharge of axonal
potentials, the interruption of target-derived factors and retrograde injury signals
transported from the site of injury to the soma are believed to enable the neuron to
respond to the trauma (Vargas and Barres, 2007; Finn et al., 2000).
WD in the PNS has always been associated with the induction of a strong
inflammatory reaction which is highly regulated by immune cells (monocytes /
macrophages, T and B lymphocytes, dendritic cells, neutrophils) and triggers a neuroinflammatory response by resident non-neuronal cells where satellite cells (SCs) are
believed to play an important role (Hawthorne and Popovich, 2011; Sanders and Jones,
2006).
1.3.1.4 .1 Satellite Cells

Satellite cells (SCs) are among the first to respond to nerve damage because of direct
contact with the nerve. Satellite cells play an important role in nerve regeneration, as it
has been shown that satellite cells proliferate, and increase in number around damaged
DRG neurons (Hanani et al., 2002; Shinder et al., 1999). They also take part in
phagocytosis of neuronal debris and up-regulate expression of a number of growth and
neurotrophic factors (Pannese, 1978).
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In addition, a significant increase in NGF and neurotrophin-3 (NT3) synthesis in
satellite cells surrounding neurons in injured DRG were seen in animal models as early
as 48 hours after nerve injury using in situ hybridization and immunohistochemical
techniques (Zhou et al., 1999). More details about satellite cells role in nerve injury will
appear in section 4 of this chapter.
1.3.1.4 .2 Schwann Cells
Myelinating and non-myelinating Schwann cells maintain axons and are vital for healthy
neurons and neuronal survival after injury. Schwann cells form a multilayered lipid
myelin sheath around large axons while small axons lack this feature as Schwann cells
ensheath them and provides support without forming myelin. Following the breakdown
of axons and myelin, Schwann cells in the distal stump undergo structural changes
within 12 to 24 hours after the injury and profound disintegration 2 to 3 days after the
injury.
Within 48 hours of injury, these Schwann cells stop producing myelin proteins
by down-regulating steady-state mRNA levels for myelin components (LeBlanc and
Poduslo, 1990), and up-regulating the regeneration-associated genes. These include
GAP-43, neurotrophins NGF, BDNF and NT-4/5 trophic factors GDNF, LIF, proinflammatory cytokines TNF, IL-1α, and IL-1β, IL-6, neuregulin and its receptors, and
growth factors such as fibroblast growth factor (FGF), interleukin-like growth factor
(IGF), ciliary neurotrophic factor (CNTF) and vascular endothelial growth factor
(VEGF) (Ide, 1996; Ishii et al., 1994; Mirsky and Jessen, 1999; Perrin et al., 2005;
Shamash et al., 2002).
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Schwann cells fragment their own myelin sheaths and have a role in the removal
of the debris of WD by sequestration of small coils of myelin debris for phagocytosis.
Phagocytosis of myelin debris is achieved partly through the action of the Schwann cells
themselves, but also through haematogenous macrophages that infiltrate the injured area.
Whole immune system plays a considerable role in nerve injury, the primary function is
known to be mediated by resident cells (such as Schwann cells, resident macrophages
and fibroblasts) because blood-borne monocytes infiltrate the injured nerve only 2 to 3
days after injury (Mueller et al., 2003). Together macrophages and Schwann cells begin
phagocytosis of myelin debris and its clearance within 3 to 4 days after the injury, and
the clearance is completed after 12 to 14 days. Myelin debris clearance is an important
step to successful regeneration, because myelin associated proteins such as MAG,
OMgp, Nogo are known to impede and inhibit successful regeneration (Chen et al.,
2006; Schwab, 2004; Xie and Zheng, 2008).
Due to the loss of axonal contact, both myelinating and ensheathing Schwann
cells divide, reaching peak proliferation around 4 days post-injury. The myelinating
Schwann cells dedifferentiate into an immature phenotype, start proliferating
longitudinally, and line up within each basal lamina tube to form long cellular chains
known as the band of Büngner and degeneration of myelin by serving as a guiding
structure for the regenerating axons (Frostick et al., 1998; Hall, 2001; Skene, 1984;
Terenghi, 1999). It also produces molecules that help to provide a temporarily
permissive

microenvironment

for

axon

regeneration

(Hall,

2005).

This

microenvironment is usually maintained until proper target re-innervation is achieved
successfully (Grafstein, 1975).
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Approximately 2 to 20 days post injury, axoplasmic regeneration may start. This
event is associated with the increased biosynthetic capabilities of the neuron at cell
body. Extension of Schwann cells and connective tissue elements provides a pathway for
migration of axoplasm filaments into the tubules of the distal stump. Synthesis of new
axoplasm is mediated by migration along the remaining viable axon to the site of the
nerve injury. Schwann cell migration and proliferation attempt to connect the proximal
stump with the Schwann cell elements of the distal nerve stump.
The Schwann cells grow concurrently with the axoplasm and provide a
framework for axonal growth (Assmus, 1978; Ducker et al., 1969; Swaim, 1972).
Schwann cells develop protein complexes that serve as physical conduits to guide axons
to their targets. The rate of axon regrowth is limited by the extension of these Schwann
cell processes rather than by axonal growth (Son and Thompson, 1995). At this stage,
Schwann cells have switched to a regenerative phenotype, converted their function from
myelination of electrically active axons to growth support for regenerating nerve fibers
(Fu and Gordon, 1997).
Denervated Schwann cells may secrete various molecules (Carey and Bunge,
1981; Skene and Shooter, 1983), some of which have been shown to be important for
stimulating neurite growth in vitro (Richardson and Ebendal, 1982; Varon et al., 1983).
They also actively secrete neurotrophic factors, and as they are proliferating, their
numbers seem to be increased 4–17 times the original number seen in a normal nerve
(Funakoshi et al., 1993; Mosahebi et al., 2001). Regeneration requires remyelination of
the regenerated axons and the presence of myelin sheaths is evident 6 to 7 days after
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regeneration has occurred in any zone (Ducker et al., 1969; Swaim, 1972). The two main
endogenous modulators of Schwann cell remyelination are cell adhesion molecules
(CAMs) and neurotrophic factors (Frostick et al., 1998; Lundborg, 2000; Lundborg and
Rosén, 2007).
The molecular program that controls axon remyelination of denervated Schwann
cells is similar to that for differentiation of immature Schwann cells in developing
nerves, but the molecular mechanism that controls Schwann cell proliferation is different
between regeneration and development. Nodes of Ranvier appear after day 14 in the
regenerative axon. Apposition of myelin occurs for as long as one year following the
repair process. The peripheral nerve’s ability to regenerate might last approximately 12
months post injury (Peacock and VanWinkle, 1972).
1.3.1.4 .3 Macrophages
Mast cells accumulate in the endoneurium of injured nerves and secrete mediators that
contribute to the recruitment of macrophages and neutrophils Apolipoprotein-E and
Galectin-3/MAC-2, which may help drive monocyte differentiation towards the M2
phenotype tissue macrophage are produced before and during monocyte recruitment
(Moalem and Tracey, 2006; Zuo et al., 2003). The production of MCP-1 and MIP-1α,
which reaches a maximum at 1 day after injury, induces the recruitment of macrophages
to the injured nerves (Perrin et al., 2005; Toews et al., 1998).
Blood-borne monocytes, spread over the entire nerve and start nerve infiltration
from 2 to 3 days post injury. Both recruitment of monocytes and macrophage
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accumulation peaks are observed approximately 7 days after injury (Bendszus and Stoll,
2003; Mueller et al., 2003; Perry et al., 1987; Taskinen and Röyttä, 1997). This
inflammatory response is turned off two to three weeks after injury and macrophages are
rapidly eliminated (Mueller et al., 2003; Omura et al., 2005; Taskinen and Röyttä, 1997).
1.3.1.4.4 PNS Versus CNS Cellular Injury Responses
Waller`s description of WD was based on studies with transected peripheral nerves, but
the main features of WD are observed after many types of injuries (crush, transection,
chemical and/or toxic) in both the CNS and in the PNS, and are also present in the
course of neurodegenerative and demyelinating diseases, suggesting a common
triggering mechanism (Coleman and Perry, 2002). So far, we have seen the
morphological changes in a nerve following peripheral injury, but a different scenario is
observed in CNS WD. In contrast to PNS WD, CNS WD shows no signs of repair.
The CNS undergoes a phase of abortive sprouting around the injury site whereby
the newly formed axons often appeared hypertrophied, irregularly branched and ending
in clubs, points or rings as confirmed histologically by Cajal in 1928. Furthermore,
morphological and metabolic changes of the neuronal cell body after injury
(chromatolysis) and beneficial inflammatory mechanisms that occur following PNS
injury are diminished or absent following an equivalent injury to the CNS (Lieberman,
1971).
The role that Schwann cells play in PNS injury is almost absent in
oligodendrocytes in CNS although they also form myelin in the nerve fiber in the CNS.
Oligodendrocytes undergo apoptosis and are not involved in myelin debris phagocytosis
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and signalling. Therefore, CNS WD is significantly slower in the CNS and is incomplete
(Vargas and Barres, 2007). Delayed macrophage recruitment, exposure of myelin
inhibitory proteins, formation of an astroglial scar and secretion of inhibitory molecules
such as chondroitin-sulphate proteoglycans all result in a hostile microenvironment for
axon regrowth (George and Griffin, 1994) and establish irreversible loss of function of
the target organs.
1.3.1.5 PNS Molecular Changes After Injury
Injury to peripheral neurons results in a series of molecular and cellular responses that
are associated with, and that may play an important role in, the mounting of a successful
nerve regenerative response, and the ensuing recovery of function. Nerve regeneration
has been studied intensively worldwide via histological methods (Fitzgerald et al., 1967;
Orgel et al., 1972; Waris, 1978; Diamond and Jackson, 1980). Most studies on
regeneration have focused primarily on how to induce axon regrowth in the CNS.
Although the molecular details of PNS regeneration are gradually growing more in the
last decade, the current view is far from complete.
The most favorable neuronal population that serves as an ideal model to study
the interaction between peripheral regenerative mechanisms and CNS growth are the
dorsal root ganglia sensory neurons due to their unique anatomical conformation.
Neurons in the CNS lack the ability to regenerate, due in part to an unfavorable
environment for regrowth (Filbin, 2003; McGee and Strittmatter, 2003; Schwab and
Bartholdi, 1996), but also because of the irreversible reduction in the intrinsic
regenerative capacity of mature neurons (Goldberg et al., 2002).
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On the other hand, injury to a peripheral nerve triggers the initiation of complex
sequences of molecular responses that incorporate a sequence of biochemical and
morphologic alterations. These include distal axon degeneration, host cell migration and
proliferation, debris clearance, axon guidance and maturation, as well as re-innervation
of target end organs. All of these events play an important role in the successful
regenerative response and the eventual recovery of function.
There are some limitations to PNS regeneration. Although the injured nerve may
undergo repair and regrowth but the diameter of regenerated axons, their conduction
velocity and excitability remain below normal levels for a long time (Fields and
Ellisman, 1986a, 1986b). As a consequence, recovery of re-innervated organs is
incomplete and often motor and sensory functions are inadequate.
The “conditioning” nerve lesion studies of Woolf and colleagues (Chong et al.,
1999; Neumann and Woolf, 1999) showed that the peripheral nerve injury, but not the
central process, generates an enhanced axonal growth state. For decades, numerous
studies have been carried out to unravel the essential elements of the PNS regeneration
program. Protein purification, unbiased genetic methods, and assessment of candidate
genes and proteins have all been attempted, resulting in the identification of large
number of injury regulated genes and proteins. Axonal regeneration is thought to be
induced by signals initiated from the injury, including calcium spikes and the retrograde
transport and nuclear import of regeneration factors (Rossi et al., 2007). The first signs
of axon regrowth in the distal segment may take place as early as 24 hours after injury,
or may be delayed for weeks in more severe injury.

	
  
	
  
	
  

25	
  

	
  

Successful functional axonal regeneration depends on both a permissive
environment and neuronal intrinsic growth capacity. Until today, our knowledge about
the different mechanisms that activate the intrinsic growth capacity of neurons after
injury remains very limited. Each component of the PNS injured nerve reacts in an
individual manner to the injury process. The sequence begins at the proximal segment of
the cell body, proceeding to the distal segment, the injury site itself, and end up at the
target organ.
Primary sensory neurons alter their phenotype both with regard to messengers,
receptors and function after injury, so that DRG neurons adapt to the new situation by
inhibiting excitatory transmitters, enhancing inhibition and promoting survival and
regenerative mechanisms. The PNS injured neuron contributes rapidly to the arrival of
injury-induced signals by the induction of transcription factors, adhesion molecules,
growth-associated proteins and the structural components needed for axonal elongation.
The functional goal of regeneration is to replace the distal nerve segment degenerated
after injury, to re-innervate the target organs and to recover their function.
Gene microarray studies have identified a series of injury-related and
regeneration-associated genes such as regulatory receptors and transcription factor genes
whose expression is altered after injury (Costigan et al., 1998; Méchaly et al., 2006;
Xiao et al., 2002).

Here we will investigate the changes of transcription factors,

cytokines, neurotrophic factors and neuropeptides after PNS injury.
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1.3.1.5.1 Neuropeptides

Histochemical examination of lumbar DRG has characteristically revealed that 30% and
50% of neurons contain substance P (SP) and calcitonin gene related peptide (CGRP)
respectively; and 96% of the SP-positive cells also showed CGRP immunoreactivity (Ju
et al 1987a, 1987b). After PNS injury, a marked decrease in SP expression in the dorsal
horn was reported primarily by Jessell et al. in 1979. Later, Shehab and Atkinson (1986)
and McGregor et al. (1984) showed that sciatic nerve injury triggered down-regulation
of SP, cholecystokinin, somatostatin and fluoride resistant acid phosphatase (FRAP) and
up-regulation of vasoactive intestinal polypeptide (VIP) in the dorsal horn of the spinal
cord. Importantly, Shehab and his colleagues were first to show VIP upregulation in
injured neurons in the DRG whose axons have been injured following sciatic nerve
transection (Shehab and Atkinson, 1986; Shehab et al., 1986).
Subsequently, CGRP down-regulation (Dumoulin et al., 1991; Noguchi et al.,
1990; Zhang et al., 1995b) was also documented. Furthermore, other studies have also
shown an up-regulation of neuropeptide Y (NPY) (Shehab et al., 2003, 2004; Wakisaka
et al., 1991; Zhang et al., 1995b), galanin (Hökfelt et al., 1987; Villar et al., 1989) and
neurokinin-1 receptor (NK1r) (Goff et al., 1998) following peripheral nerve injury.
1.3.1.5.2 Transcription Factors
Identification of early clusters of transcription factors involved in a transcriptiondependent program that reactivates the neuron’s intrinsic axonal growth capacity (Smith
and Skene, 1997) is particularly important because early activated transcription factors
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may control subsequent events in transcriptional pathways and is likely to be one of the
first steps required to mount a cell-autonomous regenerative response.
Various genes are activated primarily to produce vast amounts of lipids and
proteins for axonal outgrowth in DRG cell bodies (Robinson, 2000). Several
transcription factors such as c-Jun (Broude et al., 1997; Jenkins and Hunt, 1991), cAMP
responsive element binding protein (CREB) (White et al., 2000), STAT3 (O’Brien and
Nathanson, 2007) and ATF3 (Tsujino et al., 2000) are up-regulated and activated.
Nerve injury triggers the transcription factor ATF3 as well as c-Jun activation
(Herdegen et al., 1991; Jenkins and Hunt, 1991; Lindwall and Kanje, 2005; Makwana
and Raivich, 2005; Pearson et al., 2003; Raivich et al., 2004; Seijffers et al., 2007;
Tsujino et al., 2000). ATF3 is rapidly induced in all axotomized sensory DRG neurons,
but also peripheral and not central axonal injury induces early ATF3 activation (Tsujino
et al., 2000). Moreover, it is well characterized that up-regulation of c-Jun is consistently
accompanied by a successful regeneration response in different injury models (Herdegen
et al., 1991; Jenkins and Hunt, 1991; Lindwall and Kanje, 2005). Gap-43, p21/Waf1’s
expression is also up-regulated after peripheral nerve injury (Hoffman, 1989; Bonilla et
al., 2002; Mason et al., 2002).
A growth cone is a motile structure formed at the tip of the growing axon during
both neuronal development and axonal regrowth after nerve injury. Skene and
colleagues have shown that GAP-43 which is considered as an important regulator of
growth cone motility during nervous system development, is highly induced after
peripheral axatomy and when overexpressed with CAP-23 in vitro, they activate an
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intrinsic growth capacity in DRG neurons similar to that induced by a conditioning
lesion (Bomze et al., 2001; Skene and Willard, 1981).
Many genes have been shown to peak in the distal stump 7 days after sciatic
injury in mice (Araki et al., 2001). However, Akt and S6 phosphorylation were detected
as early as 15 minutes after ligation (Abe et al., 2010). Several sciatic nerve studies have
shown that several molecules such as the expression of neurotrophic factor (NGF,
BDNF), development (SOX11), neuropeptides (NPY and GAL), cytokines (IL-6,
CNTF), cell death (GADD45, annexin-1 (ANXA1), HSP27, cytochrome P450 1bl1
(CYP1B1), calcium signalling (calcium channel alpha-2-delta subunit), cytoskeletal
proteins (GAP43 and SPRR1A) and other secreted molecules are involved in cell-to-cell
communication. All of these molecules may participate in the activation of neighboring
non-neuronal cells around the cell body of the injured neuron and in the distal nerve
fibers (Bomze et al., 2001; Skene and Willard, 1981). Many of these identified
transcription factors and secreted molecules control the expression of neuropeptides, ion
channel expression and their own expression.
1.3.1.5.3 Cytokines
Axonal injury activates several transcription factors through the local release of
cytokines. These include, for example, the gp130 cytokines, leukemia inhibitory factor
(LIF), interleukein-6 (IL-6) and ciliary neurotrophic factor (CNTF). Cytokines are
classical injury-induced mediators that play significant roles in the regulation of immune
responses, hemopoiesis and inflammation. Inflammation is required for successful
axonal regeneration (Barrette et al., 2008; Boivin et al., 2007). Within hours after
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neuronal injury, endoneurial levels of the early inflammatory cytokines, TNF-α and
interleukin (IL)-1 α, secreted mostly by Schwann cells, start to increase in the distal
nerve stump (Hall, 2005).
Almost all the cytokines of the IL-6 family (except CNTF) are strongly up
regulated after PNS injury, and expression levels change in non-neuronal cells in the
distal part, as well as in glial cells and even in neurons in DRGs and motor pools.
Effective IL-10 levels are reached 7 days after injury. It is then; that IL-10 gradually
down-regulates the production of cytokines reaching the lowest level about 2 to 3 weeks
after injury, thereafter, degenerated myelin is cleared (Barrette et al., 2008; Boivin et al.,
2007; Hall, 2005).
1.3.1.5.4 Neurotrophic Factors
It is well known that neurotrophic factors modulate the development, maintenance and
function of the vertebrate nervous system. They also enhance functional regeneration, by
supporting axonal growth after injury. Expression of neurotrophic factor changes within
both the proximal and distal portions. Neurotrophins such as NGF and BDNF are upregulated after peripheral nerve injury, but their role in peripheral axon regeneration is
not clear.
Neurotrophin 4/5 mRNA, as well as nerve growth factor (NGF), brain-derived
neurothrophic factor (BDNF) and glial-derived neurothrophic factor (GDNF), are upregulated in the distal stump but their roles in peripheral axon regeneration are still not
fully understood (Makwana and Raivich, 2005; Markus et al., 2002; Snider et al., 2002).
Some of these neurotrophins such as NGF, which is secreted by SC, is increased early
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after nerve injury but at 3 weeks its level decreases. Once remyelination is complete, the
expression of neurotrophins and their receptors returns to normal (Funakoshi et al.,
1993; Taniuchi et al., 1986).
1.3.1.6 Active Molecular Pathways after PNS Injury
It is now well known that injured axons initiate local activation and retrograde transport
of several mitogen-activated protein kinases MAPKs family, including Erk1/Erk2 (Hanz
et al., 2003; Perlson et al., 2005), the c-Jun N terminal kinase (JNK) (Cavalli et al.,
2005) and the protein kinase G (Sung et al., 2006).
Both in vitro and in vivo studies helped to identify molecular pathways that
follow nerve damage. Several signalling pathways have been intensively studied and
considered to be imported for promoting axonal nerve regrowth or neuronal cell death.
Studies in vitro have demonstrated that activation of PKA, Ras/PI-3K/Akt (PI-3K/Akt),
or Ras/Raf/ MAPK/ERK (MAPK/ERK) signalling pathways by neurotrophins and
GDNF could promote PNS neuronal survival and enhance neurite outgrowth (Chierzi et
al., 2005; Hetman et al., 1999; Liot et al., 2004; Soler et al., 1999).
1.3.1.6.1 p52
The discovery of p53 dates back to when it was identified as a target protein of SV40
large T antigen (Lane and Crawford, 1979; Linzer and Levine, 1979). Surprisingly, in
the same year its high level was noted in different cancer cells by many research groups
(Jenkins et al., 1984; Kress et al., 1979; Lane and Crawford, 1979; Linzer and Levine,
1979). p53 is a transcription factor famous for its role in immortalized cells (May and
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May, 1999) and it plays a very important role in the cell development from the
progression of the cell cycle to differentiation (Lohrum and Vousden, 1999).
p53 also plays a pivotal role in the determination of the cell fate through DNA
repair and genome stability (May and May, 1999; Rotter et al., 1980; Vogelstein et al.,
2000; Vousden and Lu, 2002). In addition p53 is involved in the cellular response to
stress in developing and homeostatic tissues (Mendrysa et al., 2011). A wide variety of
studies have established that the main function of p53 is the pro-apoptotic activity
through its ability to direct the cell towards programmed cell death by the activation of
the key factors of apoptosis (Brodsky et al., 2004; Liu et al., 2004; Schmitt et al., 2002;
Schumacher et al., 2001; Symonds et al., 1994) as shown in (Figure 3).

Figure 3: p53-dependent cell death in neurons.
Accumulation and transcriptional activation of p53 occurs rapidly in response to a wide variety of
insults including DNA damage, oxidative stress, metabolic compromise or excitotoxicity (Culmsee et
al., 2005).
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It has been suggested that, in order to execute its apoptotic function, p53 operates
via both intrinsic and the extrinsic pathways of apoptosis (Yu and Zhang, 2005). It
should be noted that, through regulating extrinsic apoptotic pathway, p53 plays a major
role in inducing apoptosis by chemotherapeutic agents (Liu et al., 2004; Sheikh et al.,
1998) and the main target of p53 in this pathway are the cell membrane proteins such as
Fas, DR4, and DR5 (Bouvard et al., 2000; Müller et al., 1998).
Even though, p53 mainly operates via the intrinsic apoptotic pathway in response
to a variety of cellular stressors (Willis and Adams, 2005). The cornerstone of this
pathway is the mitochondria due to the presence of the proapoptotic Bcl-2 family
member on its membrane (Symonds et al., 1994). The role of p53 in this pathway
depends on its ability to activate the key pro-apoptotic factor Bax which in turn
infiltrates the mitochondria. This liberates apoptogenic factors, including cytochrome c
and DIABLO (also known as Smac), which activates a group of aspartate-specific
proteases known as caspases (Youle and Strasser, 2008).
1.3.1.6.2 Bax
Bax is a pro-apoptotic protein that belongs to Bcl2 family found sequestered in the
cytoplasm in its tetrameric form upon receiving a stress stimuli that ultimately leads to
its migration to the mitochondria (Wolter et al., 1997), it triggers a cascade activation
leading the cell to undergo programmed cell death (Gavathiotis et al., 2008). Bax
molecules were found attached to the outer membrane of the mitochondria and the
endoplasmic reticulum (Griffiths et al., 1999; Wolter et al., 1997).
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Based on the upstream signal that leads to the activation of Bax, two models
namely a direct and indirect model have been distinguished. The direct model results
from direct attachment of Bax to apoptotic messengers such as Bid, Bim, and Puma,
while the indirect model is produced after Bax displacement from pro-survival proteins
(Chipuk and Green, 2008; Dewson and Kluck, 2009; Leber et al., 2010).
It is believed that the activation of BCL2-associated X protein (Bax) has no
return point in the cell destiny that ends up in death. Such activation requires three
indispensable steps which start with conformation change, followed by mitochondrial
translocation and finally oligomerisation that inevitably causes mitochondrial
dysfunction and apoptosis (Annis et al., 2005; Goping et al., 1998; Gross et al., 1998).
Briefly, once activated Bax and another pro-apoptotic protein Bak, translocate to
the mitochondria and form pore like complexes in the mitochondrial outer membrane
lipid bilayer that serve eventually as channels for apoptotic effectors such as cytochrome
c to migrate towards the cytoplasm. Once cytochrome c reaches the cytoplasm, it binds
to Apaf-1 and leads to the activation of a series of specific apoptotic factors such as
caspase-9, caspase-3, caspase-6 and caspase-7 leading inevitably to cell death (Dewson
and Kluck, 2009, 2009).
The pro-apoptotic molecule Bax plays a major role in cell death and axonal
regeneration. Libby et al. (2005) showed partial or complete deletion of the Bax gene in
mice protected from glaucoma. In addition, the deletion of the Bax gene did not prevent
the cell death from NMDA-induced excitotoxicity in retinal ganglia. However, it did
prevent cell death after optic nerve crush. Multiple studies have confirmed that the
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deletion of such a gene significantly reduce cell death induced following axotomy in
neonatal mice (Deckwerth et al., 1996; Kinugasa et al., 2002; White et al., 1998).
In this section, we have summarized the events known to occur after an injury in
the peripheral nervous system. Research to understand the mysteries behind the
neurobiology of peripheral nerve regeneration is still ongoing. Many cell death-related
proteins have been intensively studied in the CNS but their functional roles in PNS have
not yet been explored. One of these proteins is the Death associated protein kinase
1(DAPK1). DAPK1 signal transduction pathways and its role in the nervous system will
be addressed in details in the next section.
1.3.2 DAPK1 Signal Transduction Pathways and Its Role in the Nervous System
Death associated protein kinase 1 (DAPK1), a calcium/calmodulin (Ca2+/CaM)
regulated serine/threonine kinase, was originally identified by Deiss et al. (1995) in a
genetic screen in which an antisense library was used to detect genes necessary for
interferon (IFN-γ) -induced death in HeLa cells (Bialik et al., 2004; Tu et al., 2010).
DAPK1 positively mediates cell death in a wide array of cell systems (Cohen et al.,
1997, 1999; Deiss et al., 1995; Inbal et al., 1997; Jang et al., 2002; Pelled et al., 2002;
Raveh et al., 2001; Yamamoto et al., 2002; Lin et al., 2010).
However, several studies have shown that the activity of DAPK1 is not only
restricted to cell death as pro-survival functions of the enzyme have also been
documented showing conflicting activities by DAPK1. This paved the way for further
investigations into the role of this protein (Inbal et al., 1997; Zalckvar et al., 2009). The
DAPK1 gene is well conserved through evolution in different invertebrates such as C.
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elegans and chordates and mammals (Tong et al., 2009). This actin microfilamentassociated Ca2 +/(CaM)-dependent kinase has a unique multidomain structure, including
modules that mediate protein–protein interactions such as ankyrin repeats and the death
domain (Cohen et al., 1997).
DAPK1 is abundant in the brain (Bialik et al., 2004) and has been linked to
neuronal injury associated diseases. Its expression needs to be elucidated as it could
serve as a target for therapeutic intervention in the treatment of neurodegeneration. This
section will cover a short overview of DAPK1 cellular signal transduction and its role in
the nervous system.
1.3.2.1 DAPK1 Structure and Family Members
DAPK1 was the first member of a family of serine/threonine kinases described, that
includes at least four other kinases that share a significant homology in the catalytic
domain with DAPK1 (Inbal et al., 2000; Kawai et al., 1999). ZIP(Dlk)-kinase, a
serine/threonine kinase with a C-terminal leucine zipper domain, and DAPK1- related
protein-1 (DRP-1) are both closely related to DAPK1, and their catalytic domains show
identity with that of DAPK1 (Inbal et al., 2000; Kögel et al., 1998).
Figure 4 illustrates the multi-domain structure of DAPK1. A close examination
of DAPK1 structure shows very little difference from other kinases. DAPK1 kinase
domain has a classical 12 subdomain composition typical of all serine/ threonine
kinases, followed by a region that shares high homology with the calmodulin regulatory
domains of other kinases. DAPK1 has two P-loop motif structures with beta-sheets in
the N-terminal and alpha helices in the C-terminal. Adjacent to the latter, a catalytic
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domain for ATP binding and eight ankyrin repeats have been identified (Deiss et al.,
1995; Mosavi et al., 2004; Tereshko et al., 2001; Velentza et al., 2001) .

Figure 4: DAPK1 Multi-domain structure.
	
  

The ankyrin repeat is a 33aa motif that mediates protein-protein interactions
(Mosavi et al., 2004). The P-loop is a nucleotide ATP/GTP binding motif found in many
proteins (Saraste et al., 1990). Inbal et al., (2000) and Tereshko et al., (2001) have
reported that the crystal structure of the DAPK1 catalytic domain at high resolution
reveals an unusual highly basic structured loop in the N-terminal domain. The location
of the loop in the DAPK1 catalytic structure near the peptide recognition region raises
the possibility that this could be a site of interaction with a regulatory protein or a site of
modification in DAPK1 that would regulate its kinase activity. The cytoskeletal binding
domain mediates the interaction between proteins and the cytoskeleton (Hoeflich et al.,
2004).
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The death domain of DAPK1 is a conserved stretch of around 80aa which is
commonly found in death receptor proteins, and acts as a protein interaction domain and
a platform for the death-inducing signalling complex (DISC) formation (ChaigneDelalande et al., 2008). The serine rich C-terminal tail of DAPK1 plays a negative
feedback role to the putative function of the death domain (Feinstein et al., 1995).
The kinase domain of DAPK1 is required for its cell killing activity (Cohen et
al., 1997). However, the death association domain is important for fulfilling the function.
The cytoskeleton and ankyrin repeats are thought to be involved in subcellular targeting
of DAPK1 (Cohen et al., 1999). The multi-domain structure of DAPK1 and its
participation in various apoptotic systems imply that the protein may interact with a
wide range of intracellular components to exert its action.
1.3.2.2 DAPK1 Induced Pathways
There has been a debate for almost twenty years whether DAPK1 is a pro- or antiapoptotic kinase. Several studies have shown the involvement of DAPK1 in regulation
or execution of cell death in response to various stimuli such as death receptor
activation, cytokines, matrix detachment, ceramide3 and others (Cohen et al., 1997,
1999; Deiss et al., 1995; Inbal et al., 1997; Jang et al., 2002; Pelled et al., 2002; Raveh et
al., 2001; Yamamoto et al., 2002; Bajbouj et al., 2009).
DAPK1 is linked to both type I apoptotic and type II autophagic cell death in
both caspase-dependent and caspase-independent manners (Cohen et al., 1997). In
addition, genetic engineering techniques to overexpress wild type or mutant forms of
DAPK1 in mouse demonstrated the pro-apoptotic function of DAPK1 (Cohen et al.,
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1997; Deiss et al., 1995; Shohat et al., 2001). However, many other studies showed that
the over-expression of DAPK1 does not induce a caspase-dependent apoptosis under
normal growth conditions (Inbal et al., 1997; Jin et al., 2001). It has been suggested that,
depending on the particular cell type, the response to specific apoptosis inducers can
vary and DAPK1 can either promote (Chen et al., 2005; Cohen et al., 1999; Pelled et al.,
2002) or antagonize apoptosis (Jin et al., 2001, 2002).
1.3.2.2.1 Anti-Apoptosis
Schumacher et al. (2002) were the first research group to discover the new pro-survival
activity of DAPK1 in cells using two very established models of cell death. They found
a significant increase in DAPK1 activity in the ischemic rat hippocampus during the
recovery phase. They also showed an increase in the expression of DAPK1 mRNA and
protein level in nerve growth factor (NGF)-treated PC12 cells, which raised the
possibility of DAPK1 as a player in cell survival and regeneration (Schumacher et al.,
2002).
Northern blot and in situ hybridization analyses have showing high expression of
DAPK1 in the lungs and brain. It is important to note that such high expression was
found in neurogenesis specific areas of the brain such as post mitotic regions within
cerebral cortex, hippocampus, and cerebellar Purkinje cells (Schumacher et al., 2002;
Yamamoto et al., 1999). These other studies by Inbal et al., (1997) and Jin et al., (2002)
have documented that DAPK1 does not induce apoptosis under normal growth
conditions, DAPK1 has also been speculated to exert a cyto-protective role in cellular
homeostasis (Jin and Gallagher, 2003).
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Activation of the Ras-MAPK pathway negatively regulates the apoptotic
function of DAPK1 as the phosphorylation of DAPK1 upon the activation of RAS-ERK
pathway has been correlated with the suppression of the apoptotic activity of DAPK1
(Ballif and Blenis, 2001) (Figures 5 and Figure 6). Moreover, P90 ribosomal S6 kinase
(RSK) 1 and 2 which are downstream effectors of ERK 1/2 have recently been
demonstrated to be novel targets of DAPK1 (Roux and Blenis, 2004; Shimamura et al.,
2000) and Ser-289 has been identified (using mass spectrometry) as a novel
phosphorylation site in DAPK1, which is regulated by RSK (Anjum et al., 2005) (Figure
5 and Figure 6).
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Figure 5: DAPK1 anti-apoptosis signals transduction pathways
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Figure 6: DAPK1 apoptosis and autophagy signals transduction pathways

1.3.2.2.2 Apoptosis
It has been proven that DAPK1 is involved in multiple cell death signalling in response
to IFN-γ, TNF-α, Fas, and TGF-β (Cohen et al., 1997, 1999; Deiss et al., 1995; Inbal et
al., 1997; Jang et al., 2002; Pelled et al., 2002; Raveh et al., 2001; Yamamoto et al.,
2002; Bajbouj et al., 2009). The death-promoting effects of DAPK1 depend on multiple
factors like catalytic activity, the correct intracellular localization and the presence of the
death domain (Cohen et al., 1997, 1999). It is worthy noting that the death domain of
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DAPK1 has the ability to interact with a group of intracellular cell death mediators such
as Src (Chen et al., 2005), PDCD6 (Lee et al., 2005), FADD (Henshall et al., 2003),
TNFR1 (Cohen et al., 1999), RSK (Anjum et al., 2005) as well as many oncogenic
factors such as c-Myc, p53, E2F and ceramide 3 (Inbal et al., 2002; Lin et al., 2010;
Schumacher et al., 2002) (Figure 5 and 6).
It has been also demonstrated that the inhibition of DAPK1 mRNA translation
reduced IFN-γ induced cell death in HeLa cells (Cohen et al., 1997). DAPK1
overexpression in the neonatal fibroblast induced an ample activation of p53 and
ultimately led to cell death (Raveh et al., 2001). Another study showed that in the
absence of DAPK1, p53 was only partially unregulated in response to proliferative
signals generated by oncogene expression, which indicates that DAPK1 is an upstream
activator of p53 along this particular pathway (Martoriati et al., 2005; Raveh et al.,
2001) (Figure 6). P-p38 MAPK has been identified as an upstream regulator of DAPK1
during TNFα induced apoptosis in colorectal cancer cells (Bajbouj et al., 2009).
A significant increase in DAPK1 expression pattern has been seen 1 hour after
the exposure of hippocampal neurons to neurotoxin ceramide. Interestingly, six hours
later, huge cell death has been observed among the neuronal population (Pelled et al.,
2002). Chen et al. (2005) showed that activation of ERK in DAPK1 expressing human
erythroblast (D2) cells promotes cell death. Furthermore, bidirectional signals transuded
by DAPK1–ERK interaction promote the apoptotic effect of DAPK1 has been reported
(Feinstein et al., 1995). TSC2 is directly phosphorylated by Akt and by ERK, resulting
in functional inactivation of the TSC1–TSC2 complex and mTORC1 activation (Proud,
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2007). TSC2 negatively regulates DAPK1 by promoting its lysosome-dependent
degradation. Recently, Kang et al. (2010) demonstrated that DAPK1 mediated cell
death through interaction with DANGER (Nikolaidis et al., 2007; van Rossum et al.,
2006) (Figures 5 and 6).
1.3.2.2.3 Autophagy
The involvement of DAPK1 in Type II cell death (autophagy) may settle all
contradictory studies that have questioned the role of DAPK1, whether as a friend or a
foe to the cell. Bialik and Kimchi (2010) and Jin et al. (2001) suggested that the
dependence of investigators on assays, for activation of caspase and caspase-dependent
apoptotic events, like DNA fragmentation would have missed the autophagic component
of DAPK1 expression. Expression of activated forms of DAPK1 and DRP-1 trigger
autophagy and cell death independent of caspase activity has been reported in carcinoma
cells with nonfunctional p53 (Pelled et al., 2002).
Several recent studies have mapped DAPK1 function to distinct stages in
autophagy signalling. These include the Beclin-1/phosphatidylinositol 3-kinase (PI(3)K)
complex which is necessary for autophagosome formation, and an interaction with the
LC3 binding protein, MAP1B, which may regulate vesicle trafficking (Bialik and
Kimchi, 2010). Beclin 1, an essential autophagic protein, is a BH3-only protein that
binds Bcl-2 anti-apoptotic family members. The dissociation of Beclin 1 from Bcl-2
inhibitors is essential for its autophagic activity (Cao and Klionsky, 2007), and therefore
is tightly controlled. Zalckvar et al. (2009) have found that DAPK1 phosphorylates
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Beclin 1 on T119, a critical residue within its BH3 domain, and thus promotes Beclin 1
dissociation from Bcl-XL and result in autophagy induction (Figure 6).
Another autophagic pathway that DAPK1 induces is mammalian target of
rapamycin (mTOR) pathway. mTOR, which negatively regulates autophagy is activated
by Rheb (small GTP binding protein) that is negatively controlled by TSC1/2. It has
been shown that phosphorylation of TSC2 via various modulators including AKT/PKB,
ERK, and RSK, led to inactivation of TSC1/2 and AMP kinase. This stimulation to
TSC1/2 well activate or inhibit mTOR, respectively, (Chan, 2009) (Figure 6).
MAP1B, a microtubule lattice binding protein plays a major role in autophagy
(Halpain and Dehmelt, 2006; Wang et al., 2007) and Harrison et al., (2008) provided
evidenc for DAPK1 interaction with MAP1B and their co-localization in microtubules.
Expression of MAP1B synergized with DAPK1 to suppress growth and cell viability,
yet conversely, partial depletion of MAP1B attenuated the growth suppression activity
of over expressed DAPK1 suggesting the ability of DAPK1 to induce autophagosomes
and membrane blebbing that can be affected by DAPK1/MAP1B synergy (Harrison et
al., 2008) (Figures 5 and 6).
1.3.2.3 DAPK1 and Diseases
Emerging evidence has revealed the role of DAPK1 in tumor suppression (Inbal et al.,
1997; Raveh et al., 2001). DAPK1 expression is frequently lost in tumors due to
hypermethylation of the DAPK1 gene (Cohen and Kimchi, 2001). It is triggered by
different cell death-regulators and dysregulated in several cancer types, including nonsmall cell lung, head, neck, and pancreatic adenocarcinoma (Dansranjavin et al., 2006;
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Kim et al., 2001; Michie et al., 2010; Sanchez-Cespedes et al., 2000). In addition, it has
been shown that DAPK1 expression provides a unique mechanism that links suppression
of apoptosis to metastasis (Inbal et al., 1997).
The involvement of DAPK1 in induction of renal tubular cell death in chronic
obstructive uropathy (COU) following unilateral ureteral ligation has been considered
(Yukawa et al., 2005). In another study, DAPK1 participation in tubular cell apoptosis
following renal ischemia reperfusion injury has been characterized (Kishino et al.,
2004). It has been shown that the inactivation of DAPK1 gene transcription via
methylation may boost severity of inflammation in ulcerative colitis (Gandesiri et al.,
2012). These data suggested that DAPK1 might be an important target employed to
suppress inflammation and disease progression in UC.
Another disease in which DAPK1 has been involved in is atherosclerosis.
DAPK1 mRNA and protein is significantly increased in atherosclerotic plaques, but the
mechanism by which this occurs is not yet clear (Martinet et al., 2002). Furthermore,
DAPK1 has been implicated in the molecular response to ischemic brain injury and
apoptosis-mediated cell death in neurons (Pelled et al., 2002; Yamamoto et al., 1999,
2002). It is considered as a strong positive regulator of neuronal apoptosis in vitro and in
vivo (Pelled et al., 2002; Schori et al., 2002; Yamamoto et al., 2002).
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1.3.2.4 DAPK1 in Nervous System
1.3.2.4.1 DAPK1 in CNS
DAPK1 mRNA has been shown to be principally abundant in the adult brain (Bialik and
Kimchi, 2004). DAPK1 expression decreased remarkably in the brain immediately after
birth, limiting it to restricted mature neuronal populations such as olfactory bulb,
hippocampal formation and cerebellar Purkinje and granule cells (Tian et al., 2003a;
Sakagami and Kondo, 1997; Yukawa et al., 2004). This was based on the analysis of
patterns of DAPK1 expression observed from the 13th embryonic day (E13) and was,
thereafter, detected throughout the entire embryonic period (Yamamoto et al., 1999).
DAPK1 mRNA has been detected in the mantle and ventricular zones of the entire
neuraxis in the early stages of brain formation. This differentially regulated expression
of DAPK1 during development and its restricted expression in mature neuronal
population indicate that DAPK1 might be involved in some other neuronal functions
besides executing developmental neuronal programmed cell death (Sakagami and
Kondo, 1997).
DAPK1 has been suggested to have other functional roles such as regulating
exocytosis of neurotransmitter release by phosphorylation of syntaxin-1 (Tian et al.,
2003a) and protecting neurons during development or recovery from hypoxic-ischemic
injury (Schumacher et al., 2002). Moreover, DAPK1 has been shown to function as a
mediator of multi-types of stress signals induced by deprivation of neuronal cells from
Netrin-1, and stimulation of NMDA receptors in cerebral ischemia (Bialik et al., 2004;
Tu et al., 2010).
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Wu et al. (2011) have shown that DAPK1 inhibits microtubule (MT) assembly
by activating MARK/PAR-1 family kinases MARK1/2, which destabilize MT by
phosphorylating tau and related MAP2/4. This relation with DAPK1 has demonstrated
DAPK1 function in modulating MT assembly and neuronal differentiation. It also
provides a molecular link between DAPK1 and tau phosphorylation, an event associated
with AD pathology (Wu et al., 2011; Kim et al., 2014). DAPK1 was recently shown to
have apoptosis-independent effects on the cytoskeleton (Kuo et al., 2006) and its
association with stress fibers to induce inhibition of integrins by the cytoskeletal-binding
domain of DAPK1 has been reported (Bialik et al., 2004). DAPK1 has also been
connected with neurite outgrowth regulation in mice brain (Fujita et al., 2008).
DAPK1 interacts with neogenin, a receptor for repulsive guidance molecule
(RGM) that has diverse functions in the developing central nervous system (Fujita et al.,
2008). The same study showed that cytochrome c release from mitochondria induced by
neogenin is dependent on DAPK1. It also demonstrated that DAPK1 is required for
neogenin-induced cell death in the developing chick neural tube. Furthermore, neogenin
induced cell death is abolished in the presence of RGM which blocks DAPK1 activity.
Moreover, following NGF-induced differentiation of rat PC12 cells, DAPK1 catalytic
activity and protein levels increased drastically. These and other neuronal recovery
results indicate that DAPK1 may have a previously unexplored role in neuronal
development or regeneration following injury (Schumacher et al., 2002).
It has been shown that DAPK1 is critical for the induction of neuronal cell
apoptosis in response to various stimuli such as seizure, ischemia and ceramide in both
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cultured cells and animal models experiments (Li et al., 2006; Liu et al., 2012; Mitoma
et al., 1998; Pelled et al., 2002; Yukawa et al., 2006). Recently, DAPK1 activities have
been implicated in the molecular pathways activated during seizure-induced neuronal
death (Araki et al., 2004; Henshall et al., 2003).
DAPK1 expression was induced in a rat seizure model in regions of the brain
that were not undergoing apoptosis (Henshall et al., 2003). Augustinack et al. (2002)
showed DAPK1 protein expression was elevated in temporal lobe epilepsy. It has been
published from different distinct studies that the induction of seizures following kainic
acid administration was accompanied by significant increase in DAPK1 in the CA3
region of the rat hippocampus and more interestingly the same trends were seen
concerning p53, which suggest the interaction between the two proteins and their
involvement in cell death in this models of neurodegeneration (Araki et al., 2004;
Henshall et al., 2003).
Middle cerebral artery occlusion (MCAO) is a model used to study neuronal
death. It has been shown in line with previous studies that the induction of ischemia was
associated with an elevation in DAPK1 expression (Schumacher et al., 2002; Shamloo et
al., 2005). DAPK1-deficient mice showed a decrease in cell death following
administration of glutamate or after knockout of DAPK1 that has been shown to protect
retinal ganglion cells from glutamate toxicity (Schori et al., 2002).
It is well known that Aβ peptide is a neurotoxin and it is broadly used to mimic
Alzheimer's disease (AD) to explore the mechanisms behind neuronal death in this
neurodegenerative diseases. In an in vitro study, Cheung et al. (2011) showed that the
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exposure of cultured neurons to Aβ results in cell death which is accompanied by
activation of DAPK1. AD brain cells express a number of apoptosis related proteins
such as ZIP (Zipper Interacting Protein) kinase and Bim/BOD (Bcl-2 interacting
mediator of cell death/Bcl-2 related ovarian death gene). This increase has been
suggested to be regulated by DAPK1 expression (Engidawork et al., 2001).
Interestingly, aberrant methylation of DAPK1 has been implicated in
tumourigenesis of neurofibromas or neurofibrosarcomas (Alonso et al., 2003; GonzalezGomez et al., 2003a, 2003b). In addition, another in vitro study revealed that the
induction of cell death in ceramide-3 treated hippocampal neurons was mediated by
DAPK1 (Pelled et al., 2002). The study showed that DAPK1-deficient mice neurons
treated by acyl ceramide were less sensitive to apoptosis, implying that DAPK1 played a
central role in ceramide-induced neuronal cell death in neurons (Pelled et al., 2002).
Furthermore, the role of DAPK1 in neural cells has been shown in several vertebrate
species.
DAPK1 has been implicated in p53-mediated apoptosis, a pathway activated
following epileptic brain injury, where expression of p53 increased within the ipsilateral
hippocampus (Araki et al., 2004) (Figures 5 and 6). DAPK1 has also been studied in the
human brain and suggested as a molecular regulator of neuronal death in epilepsy
(Henshall et al., 2004). DAPK1 has also been shown to function as a mediator of multi
types of stress signals induced by deprivation of neuronal cells from Netrin-1, and
stimulation of NMDA (Bialik et al., 2004; Tu et al., 2010). Tu et al., (2010) have found
that DAPK1 has a physical and functional interaction with the NMDA NR2B subunit
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receptors in cerebral ischemia and this interaction leads to severe stroke neuronal
damage (for more details see section 3).
Taken together, these studies suggest that DAPK1 is widely involved in neuronal
cell death response to different forms of acute neuronal damage as well as multiple
neurological disorders. The current body of knowledge raises the possibility of DAPK1
as a therapeutic target for diseases characterized by rapid neurodegeneration, such as
stroke or traumatic brain injury. DAPK1 has an appreciated role in neuronal
development or recovery from injury that potentiates the future application of therapies
targeting DAPK1.
1.3.2.4.2 DAPK1 in PNS
Although extensive studies have focused on DAPK1 expression pattern in the CNS and
its role in neuronal death or survival, its presence in PNS and its role in the peripheral
nerve regeneration remain completely unexplored.
This section summarized DAPK1 signalling pathways in autophagy, apoptosis,
and stressed the important role it might play in the nervous system. The next section will
explore the DAPK1 relationship with NMDA NR2B subunits and the involvement of
NMDA NR2B proteins in neuronal death and the development and maintenance of
neuropathic pain.
1.3.3 The Role of NMDA Receptors in Neuronal Death and Neuropathic Pain
The neurotransmitter receptors in the mammalian CNS have been classified into ligandgated ion channel (ionotropic) and G-protein-coupled (metabotropic) receptors (Mayer
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and Miller, 1990; Schoepp and Conn, 1993; Sommer and Seeburg, 1992). Ionotropic
receptors are subdivided into kainite, NMDA (N methyl-D-aspartate) and AMPA (RS-aamino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptors (Barnard and Henley,
1990; Mayer and Miller, 1990; Sommer and Seeburg, 1992). It is well known that,
GABA is the main inhibitory whereas NMDA is the primary excitatory neurotransmitter
that mediates fast excitatory synaptic transmission in the CNS (Ryan et al., 2008;
Traynelis et al., 2010).
NMDA receptors are different from AMPA and kainate receptors in various
aspects like: high Ca2+ permeability, Mg2+ blockade in a voltage-dependent manner at
resting membrane potential and requires the co-agonist, glycine, for activation (Ryan et
al., 2008). NMDA receptor subunits are classified into three families: NR1 (GluN1),
NR2 A-D (GluN2A–D) and NR3 A-B (GluN3A, B) (Gonda, 2012; Laube et al., 1997).
Functional NMDA receptors are composed of the two obligatory NR1 and one or more
modulatory NR2A-D subunits (Mori and Mishina, 1995). Beside the studies done on
NR3 subunits, its functional role is still not completely understood (Meguro et al., 1992;
Paoletti and Neyton, 2007). The pharmacological and functional properties of the
NMDA receptor such as single channel conductance, Mg2+ blockade and channel
deactivation time depend on the composition of the NMDA subunit complex. Different
combinations of NMDA subunits produce unique receptors with distinctive
pharmacological and biochemical properties (Tovar and Westbrook, 1999; Traynelis et
al., 2010).
Multiple studies have shown that NMDA receptors are activated by both
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glutamate and its co-agonist glycine depending on the location of its binding sites in
NR2 and NR1 subunits respectively (Anson et al., 1998; Hirai et al., 1996; Kew et al.,
2000; Laube et al., 1997; Wafford et al., 1995). NR2 subunits show 40-70 percent
homology and are differentially expressed throughout the brain during development
(Monyer et al., 1994; Watanabe et al., 1993).
1.3.3.1 The Role of NMDA Receptors in Neuropathic pain
Neuropathic pain is a major health issue generally defined as a chronic pain state caused
by peripheral nerve injury (Bennett and Xie, 1988; Decosterd and Woolf, 2000; Kim and
Chung, 1992; Seltzer et al., 1990) or central nerve injury, or both (Campbell and Meyer,
2006; Ossipov et al., 2002).
Although, numerous studies have attempted to understand the cellular
mechanism of neuropathic pain (Campbell and Meyer, 2006; Costigan et al., 2009;
Saadé and Jabbur, 2008; Sandkühler, 2009; Devor , 2006), its etiology remains a clinical
challenge (Asano et al., 2012; Longstreth, 2005). Pain hypersensitivity manifests itself in
many forms including hyperalgesia which implies an exaggerated nociceptive response
to originally noxious stimulation, allodynia which indicates a nociceptive responses to
non-noxious stimulation and finally, spontaneous pain (Al-Chaer et al., 2000; Li et al.,
2011a, b; Zhuo, 2007). Hyperalgesia is usually linked with activity dependent changes in
the spinal cord (Dubner and Ruda, 1992), a process that may share common features of
synaptic plasticity in other neural systems (Ali and Salter, 2001; Malenka and Nicoll,
1999; Woolf and Salter, 2000). It has been speculated that synaptic plasticity contributes
to pain perception, fear and memory (Li et al., 2010). Synaptic plasticity can be defined
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as the ability of connections or synapses between two neurons to change in strength and
that has been recognized as the key mechanism for chronic pain (Li et al., 2010).
Recently, Miwa et al. (2008) have reported that NMDA NR2B receptors
accumulate on synaptic sites and are responsible for the unique properties of synaptic
function and plasticity (Miwa et al., 2008). In adding, long-term potentiation (LTP),
long-term depression (LTD) and spatial learning, which require activation of NMDA
receptors in the hippocampus, are well-characterized forms of synaptic plasticity (Ji et
al., 2003a; Li et al., 2010; Wu and Zhuo, 2009). Over the last two decades, a large body
of literature has documented the involvement of NMDA receptors in mediation of
nociception and development of spinal hyper-excitability (Bleakman et al., 2006; Haley
et al., 1990; Ren et al., 1992; Woolf and Thompson, 1991; for review see Wu and Zhuo,
2009).
Compelling evidence has accumulated over the past years, demonstrating that the
activation of NMDA receptors in the spinal dorsal horn is essential for triggering the
development and maintenance of central and peripheral sensitization (Bleakman et al.,
2006; Davar et al., 1991; Dougherty et al., 1992; Gaudreau and Plourde, 2004; Gaunitz
et al., 2002; Mao et al., 1992, 1993; Ren and Dubner, 1993; Seltzer et al., 1990; Tal and
Bennett, 1993; Ultenius et al., 2006; Urch et al., 2001; Willert et al., 2004; Woolf and
Thompson, 1991). Spinal NMDA receptors, particularly the NR2B subunit are
responsible for the development of central sensitization (Hu et al., 2009; Pedersen and
Gjerstad, 2008; Renno, 1998).
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It is well established that the nociceptive transmission pathway starts from
peripheral fibers of the DRG, which then conveys to the dorsal horn of spinal cord and,
finally, to supraspinal structures such as brain stem, thalamus, somatosensory cortex,
insular cortex, and cingulate cortex (for review see Wu and Zhuo, 2009). Not
surprisingly, NMDA receptors are present in pain pathways from peripheral DRG to the
brain. Sato et al. (1993a) reported that NR1 and NR2 subunits of NMDA receptor are
both expressed in DRG neurons. It has been shown that NMDA receptors are
synthesized in DRG neuronal somata and transported to both central terminals in spinal
cord, brainstem, trigeminal nucleus and to peripheral terminals in the skin and muscles
(Coggeshall and Carlton, 1998a; Liu et al., 1997). Morphological studies have also
demonstrated NMDARs expression on myelinated and unmyelinated axons in peripheral
somatic tissues (Carlton et al., 1995; Coggeshall and Carlton, 1998a).
Various immunohistochemical localization studies of glutamate receptors have
revealed that NMDARs are predominantly expressed on small and medium diameter
neurons (Lee et al., 2001; Sato et al., 1993b; Willcockson and Valtschanoff, 2008). In a
marked observation, a large proportion of unmyelinated peripheral axons (47%) have
been found to be immunepositive for NMDA NR1 receptors in the normal digital nerve
(Du et al., 2006). Importantly, following hind-paw inflammation, a significant increase
in the proportion of positively labelled axons was seen at the 2nd and 7th day, but not on
the 14th day (Du et al., 2006). In support to that, NR2B, NR2C, and NR2D subunits, but
not NR2A, were found to be present in peripheral nociceptive fibers of primary afferents
terminals (Chen et al., 2010).
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It has been also reported that NR1/NR2B containing NMDA receptors are
expressed in both A-fibers and C-fibers (Marvizón et al., 2002). NMDARs also have
been found to be expressed centrally in second order nociceptive neurons in the spinal
cord and medullary dorsal horn causing pain hypersensitivity after tissue injury (Ji et al.,
2003b). Normally, NMDA NR2B has a limited distribution in the superficial dorsal horn
(Boyce et al., 1999; Nagy et al., 2004) ). Remarkably, after partial chronic constriction
injury to the sciatic nerve NR2B subunits containing NMDA receptor expression was
increased while NR1 was decreased in the superficial dorsal horn, suggesting the
involvement of such receptor (NMDA NR2) in the neuropathic process (Wilson et al.,
2005).
1.3.3.1.1 Are NMDA Receptors involved in Pro-Nociception or Anti-Nociception?
Although, convincing evidence from several studies anticipated NR2B as the major
subunit involved in mediating the development and maintenance of neuropathic pain
(Abe et al., 2005; Geng et al., 2010; Iwata et al., 2007; Li et al., 2011a), considerable
controversies have also been reported regarding NMDAR’s role in nociception in the
peripheral and central terminals of primary afferent neurons (Bardoni et al., 2004;
Coggeshall and Carlton, 1998b; Du et al., 2003; Liu et al., 1997). It has been found in
multiple studies that the blockade of NMDA receptors reduces pain transmission after
noxious stimuli in animals and during chronic pain in humans (Castroman and Ness,
2002; Peles et al., 2004).
Moreover, in a behavioural study, activating NMDA receptors in normal skin led
to mechanical allodynia and hyperalgesia pain which was diminished after co-injecting
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with the NMDA antagonist MK-801 (Zhou et al., 1996). In line with that, Finch et al.
(2009) have demonstrated that the topical injection of the NMDAR antagonist,
ketamine, was able to reduce allodynia in patients with complex regional pain syndrome.
Likewise, in separate studies Davies and Lodge (1987) and Dickenson and Sullivan
(1987) have reported that NMDA antagonists inhibit the hyper-excitability of spinal cord
nociceptive neurons induced by C-fiber stimulation.
On the other hand, other studies found that NMDAR antagonists, MK-801 or
ketamine, in peripheral application had essentially no effect in decreasing inflammatory
and neuropathic pain (Aley and Levine, 2002; Sawynok and Reid, 2002). A number of
studies have clearly shown that peripheral administration of NMDAR antagonists or
genetic deletion of NR1 subunit in primary sensory neurons exert anti-hyperalgesic
action in rodents (Du et al., 2003; McRoberts et al., 2011). In another study, the deletion
of NR1 gene in peripherin-expressing DRG neurons resulted in about 75% reduction of
NR1 expression as determined by western blot analysis (McRoberts et al., 2011).
In marked contrast, in a recent study carried by Pagadala et al. (2013), in which
NR1 was selectively deleted from all DRG neurons, but not from central spinal cord,
using Advillin-Cre driver. NR1 knock-out mice (NR1-cKO), displayed mechanical and
thermal hypersensitivity, higher excitability and enhanced excitatory synaptic
transmission when compared to the wild-type. Based on these results, the authors
suggested the possible anti-nociceptive effects of NMDAR activation in primary sensory
neurons (Pagadala et al., 2013). The studies addressed above clearly state the conflicting
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roles of NMDARs in primary sensory neurons and hence it remains unsettled whether
NMDARs function as pro-nociceptive or anti-nociceptive receptors.
1.3.3.2 The role of NMDA Receptors in Neuronal Death
NMDA receptors have been documented to be involved in various physiological
function such as: brain development, learning and memory formation, excitatory
synaptic transmission and plasticity, mood control, long-term potentiation (LTP) and
long-term depression (LTD) (Banerjee et al., 2009; Collingridge et al., 2010; Fitzgerald,
2012; Ikonomidou et al., 1999; Lee et al., 1999; Traynelis et al., 2010; Yoshimura et al.,
2003). However, under pathological conditions, NMDARs can cause neuronal death by
‘excitotoxicity’ (Lee et al., 1999; Rothman and Olney, 1995; Simon et al., 1984).
Changes in glutamatergic transmission and NMDAR activation have been
considered as a common pathological event in various diseases such as stroke (Choi and
Rothman, 1990), Parkinson's disease (Turski et al., 1991), epilepsy (Sloviter, 1991),
Huntington's disease (Schwarcz et al., 1983) and Alzheimer's disease (Ułas et al., 1992).
Extensive studies have shown that regulation of NMDA receptors may take part in
psychoses and some neurodegenerative disorders (Carlsson and Carlsson, 1990; Choi,
1988). In addition, NMDAR blockers protect neurons from ischemic neuronal injuries
both in vitro (Lipton and Rosenberg, 1994; Liu et al., 2007; Rothman and Olney, 1995)
and in vivo (Chen et al., 2008;Lipton and Rosenberg, 1994; Liu et al., 2007; Rothman
and Olney, 1995; Simon et al., 1984).
Forrest et al. (1994) found that NR1 receptor subunit disruption in transgenic
mice led to an early postnatal death. Besides, Tang et al., (1999) found that NR2B
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receptor subunit overexpression in mice caused an enhanced hippocampal LTP,
sustained NMDA receptor currents and improved memory. Furthermore a series of old
and more recent studies have emphasized the role of the NMDA NR2B receptor in
various types of neuronal death (Chen et al., 2008; Choi and Rothman, 1990; DeRidder
et al., 2006; Lee et al., 1999; Liu et al., 1997; Rothman and Olney, 1986, 1995; Simon et
al., 1984; Terasaki et al., 2010; Zhou and Baudry, 2006). It has been reported that NR2B
receptors are the main activator for most death signalling transduction pathways (Lai
and Wang, 2010; Martin and Wang, 2010).
NR2B is mainly present in extra-synaptic locations (Mathur et al., 2009),
whereas NR2A occur mainly in neuronal synapses. This different distribution of NMDA
subunits lead to two opposing events, neuronal death and neuronal survival respectively
(Tovar and Westbrook, 1999; Traynelis et al., 2010).
1.3.3.3 The Relationship between NMDA NR2B Receptor and DAPK1
Recently, several proteins that contribute and interact with NMDA NR2B neuronal
death in extra-synaptic sites have been characterized (Lai and Wang, 2010; Martin and
Wang, 2010; Tu et al., 2010). DAPK1 has been considered as a novel protein that
interacts physically and functionally with the NMDA NR2B receptor in ischemic
neurons in the brain (Tu et al., 2010).
Two decades ago, Choi and Rothman (1990), and Rothman and Olney (1986)
reported that ischemia led to an excessive amount of glutamate release in the
extracellular space and the induced NMDA receptor hyper-activation that led to Ca2+
influx and neuronal cell death. Later, Tu et al (2010), found that activation of NMDA
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NR2B during stroke caused Ca2+ influx that activated the Ca2+/Cam regulated protein
kinase DAPK1. Using co-immunoprecipitation with NR2B-spcific antibodies and mass
spectrometry, Tu et al revealed that cerebral ischemia recruits DAPK1 into the NMDA
NR2B receptor protein complex in the cortex of adult mice. A constitutively active
DAPK1 phosphorylates NR2B subunit at Ser-1303, which in turn enhances the
NR1/NR2B receptor channel conductance. DAPK1-NMDA NR2B interaction acts as a
central mediator for stroke damage.

Figure 7: Proposed diagram illustrateing the differences between blockade of NMDA receptor
and NMDA NR2B-DAPK1 in stroke
NMDA NR2B-DAPK1 downstream signaling causes various neuronal events in stroke. (A) Blockade
of NMDA receptor lead to inhibition of necrosis, apoptosis and autophagy, disturbing physiological
synaptic transmission and survival signaling. (B) Blockade of NMDA NR2B-DAPK1 downstream
signaling prevents various neuronal cell death including necrosis, apoptosis and autophagy, inhibition
of cell survival probably with no effect on physiological synaptic transmission (From Shu et
al. 2014).

	
  
	
  
	
  

60	
  

	
  

Notably, disruption of this protein-protein interaction in DAPK1-NMDA NR2B
complex by designing an interference peptide NR2BCT which was able to block both
DAPK1-NMDA NR2B interaction and potentiation of NMDAR function or by DAPK1
knockdown mechanism, was able to protect neuronal cells in mice against cerebral
ischemic damage. This mechanism has been considered as a possible treatment for
stroke (Tu et al., 2010; Shu et al. 2014) (Figure 7).
Markedly, DAPK1 and NMDA NR2B are both distributed ubiquitously in the
CNS during development. In the adult both DAPK1 (Tian et al., 2003; Sakagami et al.,
1997, Yukawa et al. 2006) and NMDA NR2B (Luo et al., 1997; Charton et al., 1999)
showed a restricted expression predominantly in the hippocampus, cerebral cortex and
olfactory bulbs. Many investigators have shown NMDA NR2B expression in the PNS
(Pagadala et al., 2013; Liu et al., 1997; Coggeshall and Carlton, 1998). However,
DAPK1 expression in PNS remains unidentified.
1. 3.4 Satellite Cells and Neuropathic Pain
It has been almost two centuries since these cells were discovered by Valentin in 1839
and were given the name satellite cells by the famous Spanish neuroscientist Santiago
Ramón y Cajal in 1909 (Stephenson and Byers, 1995). The shape of satellite cells has
been the core of a long debate, whether these cells are astrocyte-like or not, but it is now
well established that they have a laminar shape and lack true processes (Hanani, 2005).
Histological examination of sensory ganglia revealed that there exists tight
connections between satellite cells and also between them and neurons (Byers and
Costello, 1988; Pannese, 1974). Satellite glial cells (SGC) outnumber neurons in the
	
  
	
  
	
  

61	
  

	
  

PNS and play a crucial protective role by forming an envelope around the cell body
(Pannese, 1981; Pannese et al., 2003). However, in contrast to its supportive and
protective functions, more recently, emerging evidence has revealed that such cells
might contribute to pain following nerve injury in different neuropathic pain models
(Huang et al., 2010; Jasmin et al., 2010; Warwick and Hanani, 2013).
Close examination of the literature shows a great focus on the role of neurons in
the processing of neuropathic pain but not many studies have been conducted on the
glial cells and their contribution to such processes that might be an outlet for winning the
clinical battle against neuropathic pain. Moreover apparent changes in the satellite cells
after nerve injury spotlights directly on such cells regarding involvement in neuropathic
pain. Indeed, several studies have also shown the incrimination of glial cells in the
exacerbation of neuropathic pain.
1.3.4.1 Activation of SGC after PNS Injury
	
  GFAP, a marker of satellite cells in the PNS and astrocytes in the CNS, had been found

to be increased noticeably by the third day after nerve transection and remained at high
levels 6 weeks later in L4 and L5 DRG (Woodham et al., 1989a). A similar observation
has been made in the satellite cells of the trigeminal ganglion (TG) in response to dental
injury (Stephenson and Byers, 1995). Also in line with such observations, many groups
were able to duplicate them in different PNS injury models such as chronic constriction
injury (CCI) (Dubový et al., 2010; Ohara et al., 2008), partial nerve ligation (Xu et al.,
2008) and L4 spinal nerve ligation (SNL) (Xie et al., 2009b).
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In support of the concept of the activation of satellite cells following PNS injury,
Arkhipova et al. (2010) recently demonstrated a significant increase in the number of
satellite cells using different sciatic nerve injury technique for example, crushing,
transection and ligation. In addition they showed an increase in the thickness of SC and
area of contacts with neurons in a rat’s dorsal root ganglia.
1.3.4.2 Role of SGC in Neuropathic Pain	
  
A study that showed the involvement of satellite glial cells (SGCs) in neuropathic pain
in an animal pain model showed a 6.5 fold increase in the gap junction between these
cells after the injury. Inhibition of formation of such gap junctions led to significant
reduction of pain intensity and opened the door to the development of gap junction
blockers as potential alternatives in pain therapy (Huang et al., 2010; Warwick et al.,
2014).	
  
The relation between neurons and satellite cells after axotomy of the infraorbital
nerve was examined by Miyagi et al.(2006). They showed an increase in the gap
junction between satellite cells and neurons during development of spontaneous pain
behavior. Furthermore, in support of that, another group succeeded in reversing such
developments by knocking out the Cx43 gene, a key protein in the formation gap
junction (Vit et al., 2006). Further studies of the relation between the two cells in the
peripheral nervous system by Cherkas et al. (2004) showed an increase in coupling
between neurons and satellite cells that coincided with a significant neuronal excitably
after infraorbital nerve transaction. Moreover, in line with the relation between neurons
and satellite cells, it has been shown that a great amount of ATP secreted from neurons
was up-taken by satellite cells and it is believed that following nerve transaction,
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neurons used the ATP as a mediator to activate satellite cells (Dubový et al., 2006;
Takeda et al., 2007).	
  
Vit et al. (2009) in a recent study attempted to reduce the pain using viral gene
therapy by effectively using an increase in GABA transmission as an inhibitory strategy
to slow down the excitability seen during neuropathic pain. The delivery of the
adenoviral vector that contained the glutamic acid decarboxylase (GAD) gene directly
into trigeminal ganglia induced significant increase of GABA synthesis mainly in
satellite glial cells that persisted even after six days. Such increase in the level of
inhibitory neurotransmitters coincided with a significant decrease in pain behavior in the
orofacial formalin models. In line with the previous study, Naik et al. (2008) provided
evidence that direct injection of a GABA receptor agonist into the dorsal root ganglion
was antinociceptive in a model of peripheral nerve injury. Taken together, data from
these studies demonstrate the therapeutic potential of directly increasing the amount of
GABA in the ganglion that functions to suppress neuronal activity that occurs in
response to nerve damage and the development of peripheral and central sensitization.
There is ample evidence that satellite glial cells are involved in the development
and exacerbation of neuropathic pain. In models of neuropathy after sciatic nerve section
and peripheral inflammation, Lu and Richardson (1991) showed an increase in the
number of glial cells in the superficial dorsal horn and lateral spinal nucleus of the spinal
cord in IFN-γ knockout mice. Lee et al., (1998) and Xie et al., (2009a) demonstrated that
a significant depletion in the concentration of NGF-β, plays a major role in the activity
and survival of neurons and enhances the pain responses of neurons in the PNS, occurs
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in the DRG following sciatic nerve injury. In order to compensate for such shortage of
NGF-β, Lindholm et al., 1987 and Matsuoka et al., (1991) found that the SGCs begin to
synthesize NGF-β, and such changes were maintained for up to 2 months (Lee et al.,
1998; Zhou et al., 1999).
It has been demonstrated that in order to treat back pain and sciatica, a medical
procedure called autologous application of nucleus pulpous is used to alleviate the pain.
However, such treatments are found to induce mechanical hyperalgesia that lasts for
more than one month. Otoshi et al., (2010) found that such hyperalgesia was
accompanied by the activation of satellite cells in the DRG and also the activated glial
cells showed a prolonged increase in GDNF expression. Such phenomena were
associated with recovery of neuronal function and a reduction of pain. In addition,
Hammarberg et al. (1996) demonstrated an elevation of GDNF mRNA in satellite cells
and Schwann cells of L4/L5 DRGs following chronic injury to the adult rat sciatic nerve
which remained high for up to five months.
The studies cited above might draw the conclusion that satellite cells play a vital
part in the pathophysiology of pain following nerve injury and interpreting the
mechanisms underlying their involvement in such phenomena might help in the
understanding of neuropathic pain.
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CHAPTER 2: MATERIALS AND METHOD
2.1 Experimental Procedures
All the experimental procedures were approved by the Animals Ethics Committee of the
College of Medicine and Health Sciences at UAEU, as well as performed in accordance
with the UK Animals (Scientific Procedures) Act, 1986.

2.2 Surgical Procedures and Sciatic Nerve Injury
Adult male Wistar rats (190–220 g) obtained from the College of Medicine and Health
Sciences animal facility (Al Ain, UAE) were anaesthetized with a mixture of ketamine
(100 mg/kg) and xylazine (20 mg/kg) delivered intraperitoneally. The skin over the right
thigh region was shaved, cleansed with 70% alcohol and then an incision was made in
the skin. The sciatic nerve was exposed and cut at the mid-thigh level proximal to its
major divisions into tibial, common peroneal and sural nerves. The skin was then
sutured using 4.0 silk sutures. The left (contralateral) sciatic nerve was left intact to
serve as an internal control. At the end of surgery, rats were transferred back to their
cages and allowed to recover for 2 hours, 7 days or 14 days.
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Figure 8: A schematic diagram showing sciatic nerve injury as peripheral nerve injury model
The peripheral nerve injury model has been used in this study. It is also showing that sciatic
nerve is formed mainly by L4 and L5 nerves with a minor contribution from L6 (Shehab et al.,
1986 and Shehab, 2009).

	
  
	
  
	
  

67	
  

	
  

2.3 Immunohistochemistry
After 2 hours (n=4), 7 days (n=4) and 14 days (n=4) of sciatic nerve injury, the rats were
deeply anesthetized with an overdose of urethane (2 ml, 25%) injected intraperitoneally
and perfused through the ascending aorta with 10% formalin in 0.1 M phosphate buffer
(pH 7.4). L4 and L5 DRG were dissected out and post-fixed in the same fixative for
another 1 hour and then stored in 30% sucrose in phosphate buffer (pH 7.4) overnight.
Left and right L4 and L5 DRG were all cut in a cryostat (15 µm) and mounted on
gelatin coated slides. Slides were then washed with PBS and treated with 50% ethanol to
enhance antibody penetration. The slides were then processed with either an
immunofluorescent or peroxidase method of immunohistochemistry according to the
protocols described previously (Shehab et al., 2003, 2004, 2008). Details of the primary
antibodies used, their sources, and concentrations are shown in Table 1. Sections were
stained with one or two of the following antibodies (DAPK1, NMDA NR2B, ATF3, and
GFAP) diluted in PBS containing 0.3% Triton and incubated overnight at room
temperature (RT).
For double immunofluorescent staining, on the following day the sections were
rinsed and were incubated for 1 hour with a mixture of Rhodamine Red-X-AffiniPure
Donkey Anti- Mouse IgG (1:100; from Jackson ImmunoResearch, West Grove, PA,
USA) and Alexa Fluor 488-AffiniPure Donkey Anti-Rabbit IgG (1:200; from Jackson
ImmunoResearch).
Because both NMDA NR2B and ATF3 antibodies were produced in rabbits, the
sections were incubated with anti-NMDA NR2B on the first day followed by Alexa
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Fluor 488-AffiniPure Donkey Anti-Rabbit IgG (1:200; from Jackson ImmunoResearch)
as a secondary antibody. Then after rinsing the sections 3 times with PBS, they were
incubated with anti-ATF3 overnight at RT followed by Rhodamine Red-X-AffiniPure
Donkey Anti- Rabbit IgG (1:100; from Jackson ImmunoResearch) for 1 hour at RT.
For triple immunofluorescent staining, sections (10 µm) were incubated with a
mixture of the following antibody (DAPK1, CGRP and IB4) overnight at RT. To reveal
IB4 binding, sections were initially incubated for 1 hour in a solution of IB4 (Vector
Laboratories; 1 mg/ml) and then incubated with goat anti-IB4 overnight. After rinsing,
the sections were incubated for 1 h with a mixture of species-specific secondary
antibodies (Rhodamine Red-X-AffiniPure Donkey Anti-Mouse IgG (1:100), Alexa Fluor
488-AffiniPure Donkey Anti-Rabbit IgG (1:200) and donkey anti-goat IgG conjugated
to Alexa 488 (1:100), all of which were obtained from Jackson ImmunoResearch, USA).
After another rinse, sections were mounted with a glycerol-saline medium. All the
antibodies were diluted in PBS (pH 7.4) containing 0.3% Triton. We have used negative
control staining in which primary antibodies were omitted and sections were incubated
with only a mixture of the above-mentioned secondary antibodies.
For peroxidase staining, sections were incubated overnight in either mouse antiDAPK1 (1:4,000) or rabbit anti-NMDA NR2B (1:8,000). After rinsing with PBS, the
sections were incubated with biotinylated anti-mouse or anti-rabbit secondary antibody
(1:500, Jackson ImmunoResearch) for one hour, followed by Extravidin peroxidase
conjugate for another one hour (1:1,000, Sigma-Aldrich, St Louis, MO, USA). Finally,
after rinsing 3 times with PBS for 5 minutes each, the slides were incubated for 5
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minutes in a solution of 3, 3′-diaminobenzidine (DAB) (25 mg/50 ml of phosphate
buffer, pH 7.4 with 7.5 µl hydrogen peroxidise (30%) and 1 ml nickel chloride (3%)
added to it). Slides were then washed, dehydrated in graded alcohol, cleared in xylene,
cover slipped and examined under a light microscope.

Antibody

DAPK1

Mouse

Dilution
(Fluorescent peroxidase)
1:250- 1:4000

ATF3

Rabbit

1:300

NMDA NR2B

Rabbit

1:500- 1:8000

GFAP

Mouse

1:400

Goat

1:5000

Rabbit

1:2000

IB4
CGRP

Species raised in

Source

BD, Biosciences, San
Diego, CA, USA
SantaCruz Biotechnology,
Santa Cruz, CA, USA
Millipore, Billerica,
MA, USA)
Vector Laboratories, Inc.,
CA, USA)
Vector Laboratories, Inc.,
CA, USA)
Peninsula Laboratories,
Bachem Group, USA

Table 1: List of primary antibodies used in this study.

Representative digital images were captured using a Zeiss AxioCamHRc Digital camera
with AxioVision 3.0 software (Carl Zeiss, Germany). Some sections were also examined
with a Nikon C1 laser scanning confocal microscope.

2.4 Quantitative Real Time PCR
After 2 hours (n=6), 7 days (n=6) and 14 days (n=6) of sciatic nerve transection the rats
were decapitated, L4 and L5 DRG were dissected and immediately left in RNA later®,
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then stored at -80°C for a later measurement of the relative gene expression of DAPK1,
NMDA NR2B (Grin2b), p38 (MAPK14), p53, Bax and Akt, ERK5 (MAPK7).
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Right Sciatic Nerve Transected

Right L4 and L5
DRG Harvested

TotRNA Pooled
and Extracted

Figure 9: Design of gene expression analysis experiments
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Total RNA was extracted using TRI Reagent® Solution (Life Technologies
Corporation, NY, USA) according to the manufacturer protocol. Quality and quantity of
the extracted RNA was estimated using NanoDrop instrument (Thermo Fisher Scientific,
DE, USA). First-strand cDNAs were prepared in duplicates from 1 µg of the extracted
RNA using MuLV reverse transcriptase (Applied Biosystems, CA, USA) and served as
template for relative gene expression analysis which was also performed in duplicates on
ABI-7500 Real Time PCR System (Applied Biosystems, CA, USA) using TaqMan
chemistry. The reaction mixture consisted of 50 ngcDNA, PCR Gold buffer, 0.375 U
AmpliTaq Gold DNA polymerase (Applied Biosystems, CA, USA), MgCl2 6.0 mM,
Rox dye 50 nM, DMSO 0.4%, Triton X-100 0.04 %, Nonidet P-40 0.04 %, Tween-20
0.04 %, forward and reverse primers and FAM-BHQ-1 labelled probe (Biosearch
Technologies, Inc., CA, USA) or (Life Technologies Corporation, NY, USA) Table. 2.
Bax, p53 and 60S acidic ribosomal protein P0 (RPLP0) primers and probes were
designed using the online RealTimeDesign™ software (Biosearch Technologies, CA,
USA) in a way that at least one of the primers was spanning an exon-intron junction
within their respective gene. DAPK1, NMDA NR2B, ERK5, Akt and p38 primers and
probes

were

acquired

from

(Life

Technologies

Corporation,

NY,

USA).

Immunofluorescence data generated by the ABI-7500 Real-Time PCR System was
subjected to analysis using the Real-time PCR Miner analysis software (Zhao and
Fernald, 2005). Calculated reaction efficiencies and CTs were then used to calculate the
relative gene expression using the delta-delta CT methodology. Results for the gene
expression were normalized with RPLP0 gene expression as a house-keeping gene.
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Primer

Sequence or Reference

RPLP0

Forwad Primer
Reverse Primer

5´-CAGAGGTGCTGGACATCACAG-3´
5´-CACATTGCGGACACCCTCTAG-3´

p53

DAPK1

Forwad Primer
Reverse Primer
Forwad Primer
Reverse Primer
Rn01442011_m1

5´-CGAGATGTTCCGAGAGCTGAATG
5´-GTCTTCGGGTAGCTGGAGTG
5´- ACCAGGGTGGCTGGGATG
5´- GTGAGTGAGGCAGTGAGGAC
(Life Technologies Corporation, NY, USA)

NMDA NR2B

Rn00680474_m1

p38

Rn00578842_m1

ERK5

Rn01466573_g1

Akt

Rn00583646_m1

Bax

(Life Technologies Corporation, NY, USA)
(Life Technologies Corporation, NY, USA)
(Life Technologies Corporation, NY, USA)
(Life Technologies Corporation, NY, USA)

Table 2: References of genes used in this study

2.5 Morphological and Statistical Analysis
Photographs of DAPK1 and ATF3 stained sections were taken using an AxioCam HRc
Digital camera with AxioVision 3.0 software to capture images (Carl Zeiss, Germany).
The resulting files were used to generate the figures in Adobe PhotoShop CS6.
AxioVision 3.0 software has been used to count number of neurons that express
DAPK1, ATF3 and merged of both in L5 DRG neurons 7 days and 14 days after sciatic
nerve transection.
AxioVision 3.0 software was also used to measure the surface area of DAPK1and NMDA NR2B-labeled neurons in the DRG.
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obvious nuclei were included in the analysis. Neuron measurements were expressed as
cross-sectional areas. Three sections per L5 ganglion from three rats were used. The
number of neurons counted for each time points were in the range of 240 to 600 neurons
from three independent animals in each group. The data were transferred to Excel
program (Microsoft) spreadsheets for further statistical and graphical analyses.
A t-test for equality of means was used to find out whether DAPK1 significantly
decreased in the injured neurons 14 days as compared with 7 days after the injury. An
ANOVA followed by a Tukey post-test was used to analyze DAPK1 and NMDA NR2B
surface size measurement results.
All data are reported as the mean ± standard error of the mean. Gene expression
results were analyzed using an ANOVA followed by a Tukey post-test. Statistical
significance was accepted at p<0.05 level. All analyses were done using Prism software
(Prism v.6 GraphPad Software Inc., San Diego, CA).
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CHAPTER 3: RESULTS

3.1 DAPK1 Gene Expression in the Dorsal Root Ganglion
The expression pattern of the genes of DAPK1, NMDA NR2B (Grin2b), p38 (MAPK14),
p53, Bax, ERK5, and Akt was measured at 2 hours, 7 days and 14 days after sciatic nerve
injury using TaqMan gene expression assay qRT PCR (n=18). The selection of genes was
based on either their documented relation with DAPK1 or their role in peripheral nerve
injury. Our goals in this experiment were: First, to investigate the expression of DAPK1
gene in the normal dorsal root ganglion (DRG) neurons. Secondly, to study the relative
expression of DAPK1 gene in DRG neurons at different times following peripheral nerve
axotomy. Thirdly, to study the relative expression of key pro- and anti-apoptotic genes of
NMDA NR2B (Grin2b), p38 (MAPK14), p53, Bax, ERK5, and Akt in relation to
DAPK1 expression at the designated time intervals.
The expression of each gene was normalised to the endogenous control gene 60S
acidic ribosomal protein P0 (RPLP0) for that sample which gives an ‘absolute
expression’ of the gene. The results showed that DAPK1 mRNA is expressed in normal
uninjured DRG neurons (Figure 10A). At an early stage (2 hours) after injury, the level
of DAPK1 was significantly increased in the injured DRG compared to uninjured DRG
on the contralateral side (p<0.05, 2.2 fold). However, at a later stage, a profound
decrease in DAPK1 levels was observed at 7 days with a further reduction at 14 days
(p<0.05, 0.4 fold) postoperatively compared with the contralateral uninjured side.
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Furthermore, we found that NMDA NR2B had a remarkable mRNA increase
pattern during the course studied as its level increased at 7 days and continued to upregulate dramatically at 14 days postoperatively (p<0.05, 3.6 fold) (Figure 10B).
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Figure 10: Real time qRT-PCR results of total DAPK1, NMDA NR2B, p53, and Bax mRNA
levels following sciatic nerve injury
DAPK1 (A), NMDA NR2B (B), p53 (C) and Bax (D) mRNA levels in injured L4 and L5 DRG
compared with the uninjured side after 2 hours, 7 and 14 days postoperatively. *p<0.05. **p<0.01
and ***p<0.001. Data are expressed as mean (±SEM).
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Figure 11: Real time qRT-PCR results of total Akt, p38, ERK5 mRNA levels following sciatic
nerve injury
Akt (A), p38 (B), ERK5 (C) mRNA levels in the injured L4 and L5 dorsal root ganglia compared
with the non-injured side at (2 hours, 7 and 14 days) after injury. *p<0.05. **p<0.01 and
***p<0.001. Data are expressed as mean (±SEM).
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3.2 The Relationship between DAPK1 and Key Pro- and Anti-Apoptotic
Genes Following Sciatic Nerve Injury
Interestingly, the expression patterns of both p53 and Bax go hand in hand with the level
of DAPK1 in DRG neurons showing an increase at early stage (3.8 fold and 3.7 fold at 2
hours respectively, p<0.01) then down-regulated at 7 and 14 days after injury (Figure
11-A, C, D). In comparison, the results revealed that injury of the sciatic nerve did not
alter the gene expression of ERK5, p38 and Akt at all studied time intervals (Figure 11
A-C).

3.3 DAPK1 protein expressions in normal DRG
The aim of this experiment was to investigate the expression pattern of DAPK1 protein
in normal intact DRG neurons. CGRP and IB4 were used as normal contents of
unmyelinated and presumably thin myelinated DRG neurons (Shehab, 2011).
The results showed that DAPK1 immunoreactivity is normally present in normal
intact L4 and L5 DRG and were discernible in small to medium-sized diameter neurons
(Figure 12). Although both IB4- and CGRP-immunoreactivities were detected in small
sized neurons, CGRP was also observed in medium- to large-sized neurons. Triple
immunofluorescent labelling showed that the vast majority of DAPK1 positive neurons
were IB4 positive (74.40%). Some DAPK1 immunofluorescent positively labelled
neurons were also CGRP (45.78 %) and some of them expressed both CGRP and IB4
(29.76%) (Figure 12).
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Figure 12: DAPK1, CGRP and IB4 triple immunostaining in normal intact L5 DRG neurons
DAPK1 (red), CGRP (green) and IB4 (blue) triple immunostaining in normal intact L5 DRG
neurons. DAPK1 immunoreactivity in normal DRG neurons was discernible primarily in small to
medium-sized diameter neurons. Triple immunofluorescent labelling showed that most of DAPK1
positive cells were IB4 positve. Moreover, some DAPK1 positive neurons co-stained both CGRP and
IB4. Confocal image with Scale bar = 50 µm.
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3.4 DAPK1 and ATF3 Protein Expressions in DRG
The aim of this experiment was to investigate the expression pattern of DAPK1 protein
in normal and injured L4 and L5 DRG neurons during various time intervals (2 hours, 7
days and 14 days) using the peroxidase method of immunohistochemistry and immunefluorescence staining. ATF3 was used as a marker for neuronal injury. The results
showed that DAPK1 was expressed in normal uninjured L4 and L5 DRG neurons and
was discernible primarily to small to medium sized diameter neurons (Figure 13D and
Figure 14D). In line with our gene expression results, our immunofluorescence labelling
showed strong immunoreactivity of DAPK1 in DRG neurons in L4 (Figure 13G) and L5
(Figure 14G) after 2 hours.
Similarly as observed with the qRT PCR technique, a decrease in
immunostaining of DAPK1 was seen after 7 days and 14 days postoperatively in L4
(Figure 13 J,M) and L5 (Figure 14 JM) DRG after injury. The immunofluorescent
double labelling showed that 76.11% (Figure 16) of DAPK1 positive cells were also
ATF3 positive in the DRG of both L4 (Figure 13-J-L) and L5 (Figure 14-J-L). However,
14 days following axotomy, significantly less neurons were double labeled (t = 4.831 df
=16) (Figure 16, p<0.001) as only 53.89% of DAPK1 positive cells were ATF3 positive
in both L4 (Figure 13M-O) and L5 (Figure 14M-O) DRG. The individual mean values
of DAPK1 immunoreactivity in injured ATF3 positive neurons for both 7 days and 14
days are provided (Table 3).
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Number of days postoperatively
7 days
14 days

Mean ± SEM
76.11 ± 3.510
53.89 ± 2.974

Difference between means:
-22.22 ± 4.600
95% confidence interval:
-31.97 to -12.47
R squared: 0٫5932, t=4.831 df=16

Table 3: Comparison between the number of DAPK1 +ve neurons in injured ATF3 +ve L5 DRG
7 days and 14 days after sciatic nerve transection.

In support of the above findings, peroxidase immunohistochemical staining
produced similar results to DAPK1 immunoreactivity after 2 hours, 7 days and 14 days
in injured L4 DRG (Figure 15 B-D) compared to the uninjured side (Figure 15 A).
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Figure 13: DAPK1 and ATF3 double immunostaining in uninjured and injured L4 DRG 2
hours, 7 days and 14 days after sciatic nerve transection.
DAPK1 (red) and ATF3 (green) double immunostaining in uninjured and injured L4 DRG 2 hours,
7 days and 14 days after sciatic nerve transection. DAPK1 immunoreactivity in uninjured (D) and
injured (G) DRG 2 hours postoperatively is discernible primarily to small to medium-sized diameter
neurons. The number of DAPK1 immunoreactive neurons decreased 7 days (J) and 14 days (M)
postoperatively. Double immunofluorescent labelling showed that most of DAPK1 positive cells
were injured neurons as they were also ATF3 positive (J-L) after 7 days of surgery. However, the
number of DAPK1 +ve neurons which are also ATF3 +ve decreased after 14 days following axotomy
in L4 (M-O). Panels A-C are images of negative control staining of DAPK1 and ATF3 respectively.
Scale bar =100µm.
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Figure 14: DAPK1 and ATF3 double immunostaining in uninjured and injured L5 DRG 2
hours, 7 days and 14 days after sciatic nerve transection
DAPK1 (red) and ATF3 (green) double immunostaining in uninjured and injured L5 DRG after 2
hours, 7 days and 14 days following sciatic nerve transection. DAPK1 immunoreactivity in uninjured
(D) and injured (G) DRG 2 hours postoperatively is discernible primarily to the small to medium
diameter neurons. The number of DAPK1 immunoreactive neurons decreased 7 days (J) and 14 days
(M) postoperatively. Double immunofluorescent labelling showed that most of DAPK1 positive cells
were injured neurons as they were also ATF3 positive (J- L) after 7 days of surgery. However, the
number of DAPK1 +ve neurons which are also ATF3 +ve decreased after 14 days following axotomy
in L5 (M-O). Panels A-C are images of negative control staining of DAPK1 and ATF3 respectively.
Scale bar =100µm.
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Figure 15: DAPK1 immunoreactivity in uninjured and injured L4 DRG 2 hours and 7 and 14
days after sciatic nerve transection as revealed by peroxidase method of immunohistochemistry.
DAPK1 immunoreactivity in uninjured (A) and injured (B) DRG 2 hours postoperatively is
discernible primarily to small to medium-sized diameter neurons. The number of DAPK1
immunoreactive neurons decreased 7 (C) and 14 days (D) postoperatively. Scale bar =100µm.

	
  
	
  
	
  

86	
  

	
  

Figure 16: Statistical analysis of DAPK1 immunoreactivety in injured L5 DRG neurons 7 and
14 days after sciatic nerve transection
DAPK1 positive neurons showed a significant decrease (p<0.001) in ATF3 positive injured neurons
14 days compared to 7 days postoperatively. Data are expressed as mean (±SEM).

3.5 DAPK1–NMDA NR2B relationship in the DRG
Since DAPK1 has been documented to play a role in neuronal death in the brain via its
interaction with NMDA NR2B protein (Tu et al., 2010), we tested this relationship in
DRG following peripheral nerve injury. Immunofluorescence staining was used to
measure the level of protein expression of DAPK1 and NMDA NR2B in the DRG 2
hours, 7 days and 14 days after sciatic axotomy.
Our results showed that NMDA NR2B is present in normal small- and mediumsized diameter DRG neurons (Figure 17E). Our immunofluorescent and peroxidase
immunohistochemistry staining also showed that a decrease occurred in the number of
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NMDA NR2B labelled neurons in ipsilateral ganglia after 7 days with a further
reduction after 14 days postoperatively in L4 DRG (Figure 17K,N and Figure 19B),
compared with the immunoreactivity in DRG from the contralateral uninjured side
(Figure 17E and Figure 19A). In addition, statistical analysis showed that 98.675% of all
DAPK1 positive neurons were co-localized with NMDA NR2B positive neurons mainly
of small to medium-size (<900 mm2) but really in large neurons (>900 mm2), using an
ANOVA followed by a Tukey test as a multiple comparison as a post test in normal L4
and L5 DRG neurons (Figure 18 and Figure 17D-F). This co-localization has been also
detected at 2 hours (Figure 17G-E), 7 days (Figure 17J-L) and 14 days (Figure 17M-O)
where all DAPK1 positively labelled neurons were also NMDA NR2B positive in L4
DRG after nerve transection and vice versa.
We have noticed that DAPK1 and NMDA NR2B followed a similar protein
immuno-labelling in the cytoplasm of small- to medium-sized DRG neurons (Figure 18)
and they both showed a clear decline in their expression levels at 14 days (Figure 17E,
J). The result of the NMDA NR2B immunostaining contradicts the NMDA NR2B gene
expression analysis where its level went high at 7 and 14 days following surgery (Figure
10B). Interestingly, the NMDA NR2B- but not DAPK1-immunoreactivity was
expressed in the DRG forming an envelope around their large-sized neurons both at 7
days (Figure 17J-L) and 14 days (Figure 17M-O) postoperatively. This expression of
NMDA NR2B around large neurons was detected in both L4 and L5 DRGs (Figure 17B)
(Figure 17M-O).
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Figure 17: DAPK1 and NMDA NR2B double immunostaining in uninjured and injured L4
DRG 2 hours, 7 days and 14 days after sciatic nerve transection
DAPK1 (red) and NMDA NR2B (green) double immunostaining in uninjured and injured L4 DRG
2 hours, 7 days and 14 days after sciatic nerve transection. DAPK1 immunoreactivity in uninjured
(D) and injured (G) DRG 2 hours postoperatively is discernible primarily in small to medium-sized
diameter neurons. The number of DAPK1 immunoreactive neurons decreased after 7 days (J) and 14
days (M) postoperatively. Double immunofluorescent labelling showed that the majority of DAPK1
positive cells were also NMDA NR2B positive (J- L) 2 hours and 7-14 days after axotomy. Panels
A-C are images of negative controls staining of DAPK1 and NMDA NR2B, respectively, Scale bar
=100µm.
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Figure 18: DAPK1 and NMDA NR2B neuronal surface size of normal DRGs neurons
DAPK1 (blue), NMDA NR2B (red) and merge (green) neuronal surface area of normal DRGs
neurons. The graph shows that DAPK1 and NMDA NR2B are co-localized in normal L5 DRG
neurons. DAPK1 and NMDA NR2B have almost the same disruption pattern and neuronal surface
are. Both DAPK1 and NMDA NR2B are mainly expressed in small to medium-sized DRG neurons.
Data represent ANOVA test using Prism version6.
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3.6 NMDA NR2B in Satellite Cells of Large Injured Neurons
Having established an increase in the NMDA NR2B immunoreactivity at 7 days and 14 days
after injury, the next experiment was designed to answer 3 questions: (i) Does NMDA NR2B
express in satellite cells? (ii) If so, does NMDA NR2B express in satellite cells around small- or
large-sized neurons in the DRG after nerve injury?

(iii) Are these neurons, which are

surrounded by NMDA NR2B immunoreactivity, injured or uninjured cells?

To answer these questions, double immunofluorescent staining of NMDA NR2B
and GFAP (glial fibrillary acidic protein) as a marker for satellite cells (n=4) and
NMDA NR2B with ATF3 as a marker for injury (n=4) was carried out. The colocalization of NMDA NR2B and GFAP immunoreactivites around large neurons
indicates an increased level of NMDA NR2B in active satellite cells 7 days after sciatic
nerve injury (Figure 20G-E). An intense immunoreactivity for co-localized GFAP and
NMDA

NR2B

was

noticed

14

days

postoperatively

(Figure

20J-L).

Our

immunofluorescent staining also showed that these large DRG neurons were injured
cells as they were all ATF3 positive at 7 days (Figure 21G-E) and 14 days (Figure 21JL) postoperatively.
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Figure 19: NMDA NR2B immunoreactivity 14 days after sciatic nerve injury in the ipsilateral
L4 DRG compared with the control contralateral side revealed with peroxidase method of
immunohistochemistry
NMDA NR2B immunoreactivity is highly expressed around large-sized neurons forming an
envelope surrounding the cell bodies in injured neurons (B) which was not observed in the uninjured
side (A). Scale bar =100µm.
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Figure 20: Effects of sciatic nerve transection after 7 and 14 days on the expression of GFAP
and NMDA NR2B in the injured L4 DRG
Effects of sciatic nerve transection after 7 and 14 days on the expression of GFAP (red) and NMDA
NR2B (green) in the injured L4 DRG. Note the down-regulation of NMDA NR2B immunoreactivity
in the small-sized neurons and its up-regulation around the large-sized neurons (H) and the upregulation of GFAP (D, G). The co-localization of NMDA NR2B and GFAP immunoreactivity (F, I)
indicates its up-regulation in the satellite cells surrounding large neurons. Scale bar =100µm.
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Figure 21: ATF3 and NMDA NR2B double immunostaining in uninjured and injured L4 DRG
after 7 and 14 days following sciatic nerve transection
ATF3 (as a neuronal injury marker, red) and NMDA NR2B (green) double immunostaining in
uninjured and injured L4 DRG after 7 and 14 days following sciatic nerve transection. NMDA NR2B
immunoreactivity was reduced in the small neurons 7-14 days postoperatively (E, H) but was upregulated in satellite cells surrounding injured large neurons (D-I). Scale bar =100µm.
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CHAPTER 4: DISCUSSION
The main aims of this study were to investigate DAPK1 expression pattern along with
key pro- and anti-apoptotic cell signaling molecules (p53, Bax, Akt, ERK5, p38 and
NMDA NR2B) and to verify the possibilities of DAPK1-NMDA NR2B interaction in
DRG neurons at 2 hours, 7 days and 14 days following sciatic nerve injury. The findings
were: DAPK1 mRNA was expressed and translated to functional protein in normal DRG
neurons. Importantly, after nerve injury a prominent increase in DAPK1 mRNA was
detected at 2 hours. However, 7 and 14 days postoperatively, DAPK1 displayed a
marked down-regulation in its mRNA and protein level. Regarding the relationship
between DAPK1 and other pro and anti-apoptotic factors, we found that DAPK1, p53
and Bax exhibited almost the same expression pattern in axotomized L4 and L5 DRG.
Furthermore, our immunostaining was in line with our DAPK1 gene expression
analysis observed an early increase in immunoreactivity followed by a reduction in the
number of positively labeled cells in a late stage. In addition, NMDA NR2B gene
expression analysis showed a continuous up-regulation at 7 days followed by further
significant increases 14 days after injury. In contrast, our immunofluorescent stain
results showed a decrease in the protein level of NMDA NR2B in DRG neurons during
the same time period. Interestingly, a strong positive NMDA NR2B immunoreactivity
appeared in the satellite cells that surrounded injured large-sized neurons in both L4 and
L5 DRG.
Taken together these results suggest that DAPK1 might have an important role,
along with other pro-apoptotic molecules and down-regulation in the NMDA NR2B in
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injured neurons, in peripheral nerve regeneration. The results might also suggest the
involvement of up-regulation of NMDA NR2B in satellite cells and not neurons in the
DRG in the development of neuropathic pain 7-14 days after peripheral nerve injury.

4.1 DAPK1 Expression in Normal DRG
DAPK1 is an intracellular protein that mediates and transmits apoptotic cell death
signals in various cells, including CNS neurons. DAPK1 expression is significantly
elevated in the rat brain in acute models of injury such as ischemia and seizure (Pelled et
al., 2002; Schumacher et al., 2002; Shamloo et al., 2005). A previous study showed that
in DAPK1 knockout mice a dramatic reduction in infarct volume and enhanced
neurological function following cerebral ischemia (Tu et al., 2010). In addition, the
DAPK1 activity level was increased in PC12 cells upon exposing to apoptotic induction,
and that inhibition of DAPK1 activity rescues the cells (Yamamoto et al., 2002).
In this study, we aimed to find out whether DAPK1 is expressed in the peripheral
nervous system and what happens after peripheral nerve injury. Our results showed that
DAPK1 mRNA is normally expressed and translated to functional protein in normal
intact uninjured L4 and L5 DRG neurons and is found primarily in the small to medium
diameter neurons. Some previous studies have shown that the over-expression of
DAPK1 under normal growth conditions does not induce a caspase-dependent apoptosis
(Inbal et al., 1997; Jin et al., 2001).
In normally developing neurons, DAPK1 not only plays the classical role of
programmed cell death in post-mitotic neurons during development, but also other
neuronal functions have been suggested. This was based on analysis of patterns of
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DAPK1 expression where DAPK1 mRNA was initially observed in the mantle and
ventricular zones of the entire neuraxis in the early stages of brain formation. This
expression decreased remarkably in the brain after birth, limiting it to restricted mature
neuronal populations including olfactory bulb, hippocampal formation, cerebellar
Purkinje and granule cells. This differentially regulated expression of DAPK1 during
development and its restricted expression in mature neuronal population indicate that
DAPK1 might be involved in some neuronal functions besides executing the
developmental neuronal-programmed cell death (Sakagami and Kondo, 1997).
Accordingly, we suggest that the presence of DAPK1 in normal DRG neurons may
associate with its normal physiological function.
In addition, our results showed that DAPK1 expression was mainly discernible in
small to medium DRG neurons. Most of DRG nociceptive neurons are small diameter
neurons (Basbaum et al., 2009). Therefore, DAPK1 may play a role in modulating
nociception in PNS.

4.2 DAPK1 expression in injured PNS
4.2.1 DAPK1 Expression at Early Stage of Peripheral Nerve Injury
This study showed sciatic nerve axotomy caused a dramatic change in DAPK1
expression pattern. As a result of injury, DAPK1 gene expression is highly up-regulated
at early stage (2 hours) in injured L4 and L5 DRG compared with contralateral uninjured
neurons. Similarly, at this time point our immunohistochemistry results showed that the
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numbers of DAPK1 positively labelled neurons were markedly increased, and localized
primarily in the neuronal cytoplasm.
It is well documented that injured neurons switch the expression of regenerationassociated genes on and off according to the regeneration program (Raivich and
Makwana, 2007; Sun and He, 2010). Raivich et al. (1991) found that sciatic nerve
axonal injury interferes with the retrograde immunofluorescence of trophic signals,
disinhibiting the normally suppressed regenerative process, within 12–24 hours
following injury. Nerve injury activates intracellular cascades like the mitogen-activated
protein kinase (MAPK) pathway and the phosphoinositide 3-kinase (PI3K) pathway in
axotomized neurons (Hammarlund et al., 2009; Kiryu et al., 1995; Liu et al., 1997;
Markus et al., 2002; Namikawa et al., 2000; Park et al., 2008; Zhou and Snider, 2005).
Although, our knowledge about DAPK1 activities in PNS is limited and all the
previously available data from CNS, in vivo and in vitro studies showed that an increase
in DAPK1 expression levels is always associated with neuronal injury events (Henshall
et al., 2003; Araki et al., 2004; Shamloo et al., 2005). Thus, we suggest that DAPK1 upregulation at this early stage may interfere with the synthesis of immediate PNS injury
response and may take part in various cell signaling pathways.

4.2.2 DAPK1 Expression at Late Stage of Peripheral Nerve Injury
Previous studies carried out in CNS, showed an increase in DAPK1 level after
hippocampus damage (Schumacher et al., 2002; Velentza et al., 2001) and ischemic
injury (Shamloo et al., 2005; Tu et al., 2010). In addition, DAPK1 activity level is
increased in PC12 cells upon exposure to apoptotic induction and inhibition of DAPK1
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activity rescues the cells (Yamamoto et al., 2002). The absence of DAPK1 has been
shown to protect neurons from a wide variety of acute toxic insults (Fujita and
Yamashita, 2014).
Recently, Kim et al (2014) have shown that DAPK1 inhibition significantly
increased microtubule assembly and accelerated nerve growth factors-mediated neurite
outgrowth. These findings were demonstrated in the CNS where axons fail to regenerate.
However, our study was performed in PNS where injured axons have the ability to
regenerate. Our data showed that a profound decrease in DAPK1 level 7 days after
peripheral nerve axotomy, with further reduction at 14 days postoperatively. This downregulation of DAPK1 in this late stage might be a part of the regenerative process and
may indicate that the decrease in this cytoskeletal-associated protein kinase is an
important component to allow regeneration, neurite outgrowth and may help in recovery
of injured DRG neurons.
We have used ATF3 as an injury marker in the nervous system (Nakagomi et al.,
2003; Ohba et al., 2003; Tsujino et al., 2000). Our results showed an increase in ATF3
expression in the cytoplasm but not the nucleus of the peripherally transected nerve at 2
hours. The increase in the cytoplasm is indicative of an increase in the synthesis of
ATF3. Once synthesized, it is then translocated to the nucleus where we observed it to
be abundantly expressed at 7 days and remain so 14 days post injury. The increase in
ATF3 expression and nuclear localization is in agreement with previously reported data
demonstrating that ATF3 increase robustly in all axotomized sensory DRG neurons
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indicating that the induction of ATF3 is part of the overall neuronal response to injury
(Averill et al., 2004; Tsujino et al., 2000).
4.3 Relationship of DAPK1 with Key Pro- and Anti-Apoptotic Genes in PNS Injury
Compelling evidence now shows the functional outcome of DAPK1 signaling is mostly
dependent on the input signal (Lin et al., 2010). We have found that the expression of
both p53 mRNA and Bax was down-regulated 7 days after injury. This pattern was
directly proportional to the decrease in the expression of DAPK1 in injured DRG
neurons suggesting that DAPK1, p53 and Bax might be regulated through a common
molecular pathway following peripheral nerve injury. Martoriati et al. (2005) have
demonstrated DAPK1 as a transcriptional target of p53 as both showed a signaling
feedback loop in which DAPK1 and p53 activated each other.
Recently, it has been shown that DAPK1 death domain (DAPK1DD) directly
bind to DNA binding motif of p53 (p53DM) and phosphorylates p53 at serine-23 (p S
23) which activates Bax and mediates ischemic neuronal death in brain (Araki et al.,
2004, Pei et al., 2014). The disrupting of DAPK1DD and p53DM interaction has been
suggested to be therapeutically effective against ischemic insults (Pei et al., 2014).
Taken together, our results suggest DAPK1 might be an upstream activator of p53,
which may activate Bax in response to sciatic nerve injury. These results are
demonstrating that DAPK1 down-regulation along with other pro-apoptotic molecules
may be a significant contributor to intrinsic regulation of PNS neuronal regeneration.
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4.4 DAPK1 and NMDA NR2B Relationship
The present study has also investigated the expression pattern of NMDA NR2B receptor
before and after sciatic nerve injury. Tu et al. (2010) recently reported that DAPK1
constitutes a specific cell death-signalling molecule that is linked directly to glutamate
receptor channels in the brain. They also demonstrated that DAPK1 physically and
functionally interacts with the NMDA NR2B receptor at extra-synaptic sites where it
acts as a central mediator for stroke damage. They further showed that DAPK1 was
recruited into the NMDA NR2B receptor protein complex in the cortex of adult mice
after cerebral ischemia (Tu et al., 2010).
In this study, the immunohistochemical staining showed that there was an
interesting relationship between the expression of DAPK1 and NMDA NR2B receptor
in the DRG neuron. The results showed that NMDA NR2B mRNA expression increased
at 7 days after sciatic nerve injury and continued to up-regulate significantly 14 days
postoperatively. In comparison, although DAPK1 was significantly increased after 2
hours, it began to decrease 7-14 days in ipsilateral DRG. The dramatic down regulation
of DAPK1 mRNA was shown after 14 days of sciatic nerve transection. These results
have been further investigated immunohistochemically.
The expression of NMDA receptors has been already established in previous
studies, which demonstrated that they are expressed in the cell bodies of primary
afferent neurons (Ma and Hargreaves, 2000; Sato et al., 1993; Shigemoto et al., 1992)
and are found on peripheral primary afferent processes (Carlton and Hargett, 1995;
Cincotta et al., 1989; Coggeshall and Carlton, 1998a; Kinkelin et al., 2000). It has also
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been shown that glutamate receptors are predominantly expressed on small- and
medium-sized neurons (Lee et al., 2001; Sato et al., 1993; Willcockson and
Valtschanoff, 2008). Our data came in agreement with these previous works and further
illustrated that DAPK1 and NMDA NR2B are co-localized in normal and injured smallto medium- sized neurons in the DRG.
Yan et al., 2013 have reported the up-regulation of NMDA NR2B 7 days after
injury using a western blot, which came aligned with our gene expression analysis
results. Surprisingly, our studies using immunohistochemistry staining have revealed
that the proportion of NMDA NR2B labelled neurons decreased at 7 days and 14 days
after sciatic nerve injury. However, this down regulation of NMDA NR2B in the
neurons was accompanied with an up-regulation in the population of glial cells
surrounding large-sized injured neurons (> 30 µm). This observation may provide an
explanation of why we have found an increase in NMDA NR2B mRNA.
Although not much is known about the responses of satellite cell to nerve injury,
there is evidence that these cells increase the expression of the glial marker GFAP in
DRG (Woodham et al., 1989;

Zhou et al., 1996; Hu et al., 2007). Our

immunofluorescent double labelling staining revealed that GFAP and NMDA NR2B are
co-localized in satellite cells of the large injured neurons in L4 and L5 DRG 14 days
after injury, as they were also ATF3 positive.
It has been demonstrated that NR2B receptors are the main activators for most
death signaling transduction pathways (Lai and Wang, 2010; Martin and Wang, 2010).
Moreover, it has been reported that uncoupling of activated DAPK1 from the NMDA
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receptor complex protects against brain damage in stroke without affecting the
physiological actions of the NMDA receptors, as total blockade of NMDA receptor
could be deleterious to animals and humans. Thus, targeting DAPK1-NMDA NR2B
receptor interaction or inhibition of DAPK1 has been considered as a practical strategy
for stroke therapy (Tu et al., 2010; Martin and Wang, 2010; Shu et al	
  2014). These
findings are in line with our results, which demonstrate that DAPK1 might have a
physical and functional association with NMDA NR2B in the PNS. We proposed that
down-regulation of DAPK1 and NMDA NR2B following sciatic nerve injury might be
the pathway that promotes neuronal survival and sheds light on the mechanisms of
peripheral nerve regeneration.

4.5 DAPK1-NMDA NR2B and Pain
There is considerable evidence that glutamate receptors are major contributors to the
development and maintenance of neuropathic pain (Carlton and Hargett, 1995; Coderre
and Melzack, 1992; Dickenson and Sullivan, 1987; Keast and Stephensen, 2000; Woolf
and Thompson, 1991). It is known that peripheral NMDA receptor activation contributes
to nociception activation, mechanical sensitivity and heat sensitization after PNS injury
(Du et al., 2003a). The NMDA NR2B receptor has been shown to play a crucial role in
neuropathic pain (Boyce et al., 1999; Laurie et al., 1997; Nagy et al., 2004). Yet, we
know little about how nerve injury alters responses to this neurotransmitter in primary
sensory neurons.
One important component in the findings of this study was that both DAPK1 and
NMDA NR2B were down-regulated in L4 and L5 DRG neurons 14 days after peripheral
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nerve injury. This has been confirmed by NMDA NR2B and ATF3 double
immunofluorescence staining, which showed that both DAPK1 and NMDA NR2B were
negative in many positively labeled ATF3 injured neurons 14 days after nerve injury. It
has been known that after this postoperative period of time following sciatic nerve injury
the inflammatory response is turned off 2-3 weeks after injury and macrophages are
rapidly eliminated (Mueller et al., 2003; Omura et al., 2005; Taskinen and Röyttä, 1997).
Another striking finding that DAPK1-expressing dorsal root ganglion cells costained for markers of nociceptive neurons, such as CGRP and IB4. Furthermore, our
data showed complete co-localization of DAPK1 and NMDA NR2B in small-sized
diameter neurons in the DRG which are responsible for pain transmission from the
periphery to the spinal cord. Several studies documented that small diameter peptidergic
neurons co-express NMDA receptors and knockdown of NMDA receptors in DRGs
reduced pain behavior (Ma and Hargreaves, 2000; McRoberts et al., 2011). Most DRG
nociceptive neurons are small diameter neurons (Basbaum et al., 2009).
Although, convincing evidence from several studies anticipated NR2B as the
major subunit involved in mediating the development and maintenance of neuropathic
pain (Abe et al., 2005; Geng et al., 2010; Iwata et al., 2007; Li et al., 2011), extensive
controversies have been reported regarding NMDAR’s roles in nociception in the
peripheral and central terminals of primary afferent neurons. Indeed, whether NR2B has
a pro-nociceptive or anti-nociceptive role remains an unsettled issue (Bardoni et al.,
2004; Coggeshall and Carlton, 1998b; Du et al., 2003b; Liu et al., 1997).
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Thus, the most parsimonious explanation for our finding was that DAPK1
activated NMDA NR2B in the early stage in this study of nerve injury, conversely, both
become down-regulated at later stages after 7 and 14 days, which might indicate their
participation in modulating nociception in the PNS.

4.6 The Relationship of the Expression of NMDA NR2B in Satellite Cells and
Pain
As in our gene expression analysis, previous study (Yan et al., 2013) showed that
NMDA NR2B is up-regulated in DRG and suggested its role in development of
neuropathic pain. However, our results using an immunohistochemical method
distinctively showed that NMDA NR2B is down-regulated in DRG neurons which might
argue against its involvement in neuropathic pain. Interestingly, we found an upregulation of NMDA NR2B in satellite cells 7-14 days following sciatic nerve injury
suggesting the involvement of NMDA NR2B in neuropathic pain via these glial cells
and not neurons.
A series of older and recent studies have emphasized the importance of glial cells
in the maintenance of neuropathic pain (Hanani et al., 2002; Pannese et al., 2003; Xu et
al., 2008; Xie et al., 2009). These glial cells, as well as neurons have been documented
to contribute in neuropathic pain. Shinder and Devor (1994) observed that satellite cells
formed several layers around neurons after axotomy of the sciatic nerve and having the
appearance of “onion bulbs”. The satellite cell phenomena was seen only around large
neurons (Liu et al., 2012).
GFAP was used based on its well-known role as satellite cells activation marker
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(Dubový et al., 2010; Gunjigake et al., 2009; Ohara et al., 2008; Stephenson and Byers,
1995; Takeda et al., 2007; Vit et al., 2006; Xie et al., 2009; Xu et al., 2008; Zhou et al.,
1996; Hu et al., 2007), and found that after spinal nerve ligation (SNL) satellite cell
activated and wrapped all types of DRG neurons as early as 12 hours postoperatively,
but the distribution of GFAP shifted from small and medium to be concentrated around
large DRG neurons 7 days after injury (Liu et al., 2012).
This expression of GFAP in satellite cells of large DRG neurons has been also
shown after chronic constriction (CCI) in previous studies or transection of the rat sciatic
nerve (Zhou et al., 1996; Hu et al., 2007). Although, it is known that Aβ fibers which
originate from large neurons in the DRG are involved in the transmission of innocuous
sensory information, it has been reported that a significant number (about 20% in rats
and >50% in rodents) of large fibres are also nociceptive (Djouhri and Lawson, 2004).
This observation has been described in other studies which have shown that large Aβfiber DRG neurons contributed in mechanical allodynia in SNL rats (Song et al., 2003;
Xie et al., 2005), although very little is known about the underlying molecular
mechanism of how they initiate pain.
In support of this observation, Hanani et al. (2002) have examined satellite cells
in mouse DRG 14 days after PNS injury, and they found a great increase in gap
junction-mediated coupling between satellite cells enveloping different neurons reached
6-fold suggesting that new gap junctions formed between satellite cells and suggested
possible interaction of satellite cells in neuropathic pain. Further research has
documented the up-regulation of the gap junction protein, connexin 43 and a decrease in
membrane resistance (Ohara et al., 2008; Pannese et al., 2003). Inhibition of such
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phenomena from occurring by injection gap junction blockers led to significant
reduction of pain behaviour and opened the door to studies on gap junction blockers that
may have a potential in pain therapy (Huang et al., 2010; Warwick et al., 2014).
Our results showed that NMDA NR2B co-expressed with GFAP in activated
satellite cells that surrounded large DRG neurons 7 and 14 days after injury. Taken
together, we show here for the first time the up-regulation of NMDA NR2B in satellite
cells 7 days and 14 days after PNS injury. This up-regulation may be the link between
the mechanisms of NMDA NR2B and satellite cells in the development and
maintenance of neuropathic pain.
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CHAPTER 5: CONCLUSION

In this study, the DAPK1 expression pattern has been investigated for the first time in
normal L4 and L5 DRG neurons and after sciatic nerve injury. This study showed that:
•

DAPK1 is present in normal DRG neurons. The down-regulation of DAPK1
following sciatic nerve injury along with other vital pro-apoptotic players and
NMDA NR2B down-regulations might promote neuronal survival and shed light
on the mechanisms of peripheral nerve regeneration.

•

Peripheral DAPK1-NMDA NR2B co-localization in nociceptive neurons might
indicate DAPK1-NMDA NR2B participation in modulating nociception in the
PNS. NMDA NR2B expression in the satellite cells might suggest that NMDA
NR2B modulate neuropathic pain through satellite cell, and not through neurons,
after 7 and 14 days of peripheral nerve injury.

In conclusion, the results of this study have shown that DAPK1 is present in the
sensory neurons and it might be a master regulator of neuropathic pain as well as
play a role in driving the intrinsic growth ability and recovery from injury. A deeper
understanding of the complex regulation of peripheral DAPK1-NMDA NR2B as a
regulator of both axonal regeneration and neuropathic pain might help in designing
genetic and pharmacological strategies to promote faster neuronal repair and
regeneration. The field of study would benefit immensely from investigation into the
cellular, molecular, systemic, and behavioural levels underlying these processes.
Understanding neuronal and glial mechanisms in neuropathic pain offers hope of
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developing drugs targeting DAPK1-NMDA NR2B or NMDA NR2B satellite cellrelated molecules.
5.1 DAPK1 in Nervous system
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Figure 22: Diagrams illustrate DAPK1 and NMDA NR2B protein expression in DRG neurons
following peripheral nerve injury
The down-regulation of DAPK1-NMDA NR2B in small to medium neurons may have a significant
contribution in intrinsic regulation of PNS regeneration. The up-regulation of NMDA NR2B in
activated satellite cells 7-14 days after PNS injury may indicates that NMDA NR2B modulate
neuropathic pain through satellite cells in this time period.
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Figure 23: DAPK1 in CNS
DAPK1-NMDA NR2B and DAPK1- p53 physically and functionally interact in the brain and their
expression level up-regulated in brain injury/diseases which leads to neuronal cell death (modified
from Tu et al., 2010 and Pei et al., 2014).

Figure 24: DAPK1 suggested working model in PNS in this study
Suggested working model of DAPK1 in the PNS. DAPK- NMDA NR2B and DAPK1- p53
expressions are down-regulated in the DRG after PNS injury to rescue cells from death.
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5.2 Future Direction
The establishment of the expression pattern of DAPK1 in normal DRG neurons and
following PNS injury in this study, has opened doors for further research to explore
DAPK1 signal transduction pathways, mechanism and its role in the PNS. Investigating
DAPK1 expression pattern in axons of normal and injured DRG neurons and its possible
role in growth cone function will further enlighten the role of DAPK1 in PNS axonal
regrowth and regeneration. In addition, studying the effect of DAPK1 inhibition in the
expression pattern of key pro- and anti-apoptotic molecules such as p53, Bax and
NMDA NR2B will enhance our understanding of its molecular activities in PNS.
Moreover, DAPK1 knockout mice will help us to settle its contribution in PNS
nociception and regeneration. Indeed, this study put the first stone in shedding light to
understand the possible role of DAPK1 in the peripheral nervous system.
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